UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

10-Q

(Mark One)

QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934

For the

quarterly
period ended
March 27, June 26, 2021

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT
OF 1934

For the transition period from ____________ to ____________

Commission File Number:

0-27078

HENRY SCHEIN, INC.

(Exact name of registrant as specified in its charter)

Delaware
11-3136595
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)

Delaware

11-3136595

(State or other jurisdiction of

(I.R.S. Employer Identification No.)

incorporation or organization)

135 Duryea Road

Melville,

,
New York

(Address of principal executive offices)

11747

(Zip Code)

(
631
)

(631) 843-5500

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $.01 per share
HSIC
The Nasdaq Global Select Market

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $.01 per share

HSIC

The Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required

to be filed by Section 13 or 15(d) of the Securities
Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.
Yes
No

Yes

No

Indicate by

check mark
whether the registrant
has submitted
electronically every Interactive
Data File
required to
be submitted
pursuant
to
Rule
405
of
Regulation
S-T
during
the
preceding
12
months
(or
(or for
such
shorter
period
that
the
registrant
was
required to submit such files).
Yes
No

Yes

No

Indicate by

check mark
whether the
registrant is
a large
accelerated filer,
an accelerated
filer,
a non-accelerated
filer,
a smaller
reporting
company,
or
an
emerging
growth
company.
See
the
definitions
of
“large
“large accelerated
filer,”
“accelerated
“accelerated filer,”
“smaller “smaller reporting company,” and “emerging growth company”
in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period

for
complying with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined

in Rule 12b-2 of the Exchange Act).
Yes
No

Yes

No

As of AprilJuly 26, 2021

,there were
140,696,094
139,693,210 shares of the registrant’s common stock outstanding.


HENRY SCHEIN, INC.

INDEX

PART I. FINANCIAL INFORMATION

Page

ITEM 1.

Consolidated Financial Statements:

Balance Sheets as of June 26, 2021 and December 26, 2020

3

Statements of Income for the three and six months ended

June 26, 2021 and June 27, 2020

4

Statements of Comprehensive Income for the three and six months ended

June 26, 2021 and June 27, 2020

5

Statement of Changes in Stockholders' Equity for the three months ended

June 26, 2021 and June 27, 2020

6

Statement of Changes in Stockholders' Equity for the six months ended

June 26, 2021 and June 27, 2020

7

Statements of Cash Flows for the six months ended

June 26, 2021 and June 27, 2020

8

Notes to Consolidated Financial Statements

9

Note 1 – Basis of Presentation

9

Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted

and Recently Issued Accounting Standards

10

Note 3 – Revenue from Contracts with Customers

11

Note 4 – Segment Data

12

Note 5 – Debt

13

Note 6 – Leases

16

Note 7 – Redeemable Noncontrolling Interests

18

Note 8 – Comprehensive Income

18

Note 9 – Fair Value Measurements

20

Note 10 – Business Acquisitions

22

Note 11 – Plans of Restructuring

23

Note 12 – Earnings Per Share

24

Note 13 – Income Taxes

25

Note 14 – Derivatives and Hedging Activities

26

Note 15 – Stock-Based Compensation

27

Note 16 – Supplemental Cash Flow Information

29

Note 17 – Legal Proceedings

30

Note 18 – Related Party Transactions

32

ITEM 2.

Management's Discussion and Analysis of

Financial Condition and Results of Operations

34

ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

53

ITEM 4.

Controls and Procedures

54

PART II. OTHER INFORMATION

ITEM 1.

Legal Proceedings

55

ITEM 1A.

Risk Factors

55

ITEM 2.

Unregistered Sales of Equity Securities and Use of Proceeds

55

ITEM 6.

Exhibits

56

Signature

57

 I.FINANCIAL INFORMATION

Page


3
4
5
6
7
8
8
9
10
11
12
15
17
17
19
21
22
23
24
25
26
28
28
31
32
46
47
48
48
48
49
50
See accompanying notes.
3

PART

I. FINANCIAL INFORMATION

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

HENRY SCHEIN, INC.

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

 

 

June 26,

 

December 26,

 

 

 

 

 

2021

 

2020

 

 

 

 

 

(unaudited)

 

 

 

ASSETS

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

167,228

 

$

421,185

 

Accounts receivable, net of reserves of $81,113 and $88,030

 

 

1,356,881

 

 

1,424,787

 

Inventories, net

 

 

1,688,210

 

 

1,512,499

 

Prepaid expenses and other

 

 

529,929

 

 

432,944

 

 

 

Total current assets

 

 

3,742,248

 

 

3,791,415

Property and equipment, net

 

 

358,224

 

 

342,004

Operating lease right-of-use assets

 

 

301,440

 

 

288,847

Goodwill

 

 

2,722,974

 

 

2,504,392

Other intangibles, net

 

 

604,515

 

 

479,429

Investments and other

 

 

394,665

 

 

366,445

 

 

 

Total assets

 

$

8,124,066

 

$

7,772,532

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

Accounts payable

 

$

903,859

 

$

1,005,655

 

Bank credit lines

 

 

72,105

 

 

73,366

 

Current maturities of long-term debt

 

 

9,839

 

 

109,836

 

Operating lease liabilities

 

 

75,008

 

 

64,716

 

Accrued expenses:

 

 

 

 

 

 

 

 

Payroll and related

 

 

313,892

 

 

295,329

 

 

Taxes

 

 

156,176

 

 

138,671

 

 

Other

 

 

562,762

 

 

595,529

 

 

 

Total current liabilities

 

 

2,093,641

 

 

2,283,102

Long-term debt

 

 

706,487

 

 

515,773

Deferred income taxes

 

 

46,528

 

 

30,065

Operating lease liabilities

 

 

243,232

 

 

238,727

Other liabilities

 

 

423,416

 

 

392,781

 

 

 

Total liabilities

 

 

3,513,304

 

 

3,460,448

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

 

604,081

 

 

327,699

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

 

 

 

 

Preferred stock, $0.01 par value, 1,000,000 shares authorized,

 

 

 

 

 

 

 

 

NaN outstanding

 

 

0

 

 

0

 

Common stock, $0.01 par value, 480,000,000 shares authorized,

 

 

 

 

 

 

 

 

139,780,841 outstanding on June 26, 2021 and

 

 

 

 

 

 

 

 

142,462,571 outstanding on December 26, 2020

 

 

1,398

 

 

1,425

 

Additional paid-in capital

 

 

0

 

 

0

 

Retained earnings

 

 

3,465,647

 

 

3,454,831

 

Accumulated other comprehensive loss

 

 

(106,779)

 

 

(108,084)

 

 

Total Henry Schein, Inc. stockholders' equity

 

 

3,360,266

 

 

3,348,172

 

Noncontrolling interests

 

 

646,415

 

 

636,213

 

 

 

Total stockholders' equity

 

 

4,006,681

 

 

3,984,385

 

 

Total liabilities, redeemable noncontrolling interests and stockholders' equity

 

$

8,124,066

 

$

7,772,532

See accompanying notes.

3


March 27,
December 26,
2021
2020
(unaudited)
ASSETS
Current assets:
Cash and cash equivalents
$
144,538
$
421,185
Accounts receivable, net of reserves of $
79,936
and $
88,030
1,317,546
1,424,787
Inventories, net
1,626,185
1,512,499
Prepaid expenses and other
482,356
432,944
Total current assets
3,570,625
3,791,415
Property and equipment, net
353,248
342,004
Operating lease right-of-use assets
301,759
288,847
Goodwill
2,587,438
2,504,392
Other intangibles, net
597,619
479,429
Investments and other
369,231
366,445
Total assets
$
7,779,920
$
7,772,532
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable
$
909,575
$
1,005,655
Bank credit lines
67,415
73,366
Current maturities of long-term debt
111,176
109,836
Operating lease liabilities
68,580
64,716
Accrued expenses:
Payroll and related
286,106
295,329
Taxes
146,755
138,671
Other
533,161
595,529
Total current liabilities
2,122,768
2,283,102
Long-term debt
506,461
515,773
Deferred income taxes
42,254
30,065
Operating lease liabilities
248,624
238,727
Other liabilities
410,184
392,781
Total liabilities
3,330,291
3,460,448
Redeemable noncontrolling interests
452,899
327,699
Commitments and contingencies
Stockholders' equity:
Preferred stock, $
0.01
par value,
1,000,000
shares authorized,
NaN
outstanding
0
0
Common stock, $
0.01
par value,
480,000,000
shares authorized,
141,310,113
outstanding on March 27, 2021 and
142,462,571
outstanding on December 26, 2020
1,413
1,425
Additional paid-in capital
0
0
Retained earnings
3,493,060
3,454,831
Accumulated other comprehensive loss
(136,305)
(108,084)
Total Henry Schein, Inc. stockholders' equity
3,358,168
3,348,172
Noncontrolling interests
638,562
636,213
Total stockholders' equity
3,996,730
3,984,385
Total liabilities, redeemable noncontrolling
interests and stockholders' equity
$
7,779,920
$
7,772,532
See accompanying notes.
4

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS

OF INCOME

(in thousands, except per share data)

(unaudited)

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

 

2021

 

2020

 

2021

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

2,967,223

 

$

1,684,399

 

$

5,892,184

 

$

4,113,270

Cost of sales

 

 

2,077,472

 

 

1,230,133

 

 

4,111,582

 

 

2,912,990

 

 

Gross profit

 

 

889,751

 

 

454,266

 

 

1,780,602

 

 

1,200,280

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

678,801

 

 

445,765

 

 

1,336,793

 

 

1,013,127

 

Restructuring costs

 

 

604

 

 

15,934

 

 

3,535

 

 

20,721

 

 

Operating income (loss)

 

 

210,346

 

 

(7,433)

 

 

440,274

 

 

166,432

Other income (expense):

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,357

 

 

1,997

 

 

3,340

 

 

5,187

 

Interest expense

 

 

(6,376)

 

 

(10,486)

 

 

(12,861)

 

 

(18,298)

 

Other, net

 

 

354

 

 

(291)

 

 

663

 

 

(511)

 

 

Income (loss) from continuing operations before taxes,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

equity in earnings of affiliates and noncontrolling interests

 

 

205,681

 

 

(16,213)

 

 

431,416

 

 

152,810

Income tax benefit (expense)

 

 

(48,027)

 

 

950

 

 

(104,712)

 

 

(36,960)

Equity in earnings of affiliates

 

 

6,323

 

 

1,411

 

 

12,201

 

 

4,145

Net income (loss) from continuing operations

 

 

163,977

 

 

(13,852)

 

 

338,905

 

 

119,995

Income from discontinued operations, net of tax

 

 

0

 

 

585

 

 

0

 

 

303

Net income (loss)

 

 

163,977

 

 

(13,267)

 

 

338,905

 

 

120,298

 

Less: Net (income) loss attributable to noncontrolling interests

 

 

(8,261)

 

 

2,470

 

 

(17,192)

 

 

(834)

 

Plus: Net loss attributable to noncontrolling interests

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

from discontinued operations

 

 

0

 

 

0

 

 

0

 

 

0

Net income (loss) attributable to Henry Schein, Inc.

 

$

155,716

 

$

(10,797)

 

$

321,713

 

$

119,464

Amounts attributable to Henry Schein Inc.:

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations

 

$

155,716

 

$

(11,382)

 

$

321,713

 

$

119,161

Discontinued operations

 

 

0

 

 

585

 

 

0

 

 

303

Net income (loss) attributable to Henry Schein, Inc.

 

$

155,716

 

$

(10,797)

 

$

321,713

 

$

119,464

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share from continuing operations attributable to Henry Schein, Inc.:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.11

 

$

(0.08)

 

$

2.28

 

$

0.84

 

Diluted

 

$

1.10

 

$

(0.08)

 

$

2.26

 

$

0.84

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share from discontinued operations attributable to Henry Schein, Inc.:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

0

 

$

0

 

$

0

 

$

0

 

Diluted

 

$

0

 

$

0

 

$

0

 

$

0

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings (loss) per share attributable to Henry Schein, Inc.:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

$

1.11

 

$

(0.08)

 

$

2.28

 

$

0.84

 

Diluted

 

$

1.10

 

$

(0.08)

 

$

2.26

 

$

0.84

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average common shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

 

140,358

 

 

142,350

 

 

141,316

 

 

142,654

 

Diluted

 

 

141,657

 

 

142,350

 

 

142,538

 

 

142,654

(unaudited)

See accompanying notes.

4


Three Months Ended
March 27,
March 28,
2021
2020
Net sales
$
2,924,961
$
2,428,871
Cost of sales
2,034,110
1,682,857
Gross profit
890,851
746,014
Operating expenses:
Selling, general and administrative
657,992
567,362
Restructuring costs
2,931
4,787
Operating income
229,928
173,865
Other income (expense):
Interest income
1,983
3,190
Interest expense
(6,485)
(7,812)
Other, net
309
(220)
Income from continuing operations before taxes, equity in
earnings of affiliates and noncontrolling interests
225,735
169,023
Income taxes
(56,685)
(37,910)
Equity in earnings of affiliates
5,878
2,734
Net income from continuing operations
174,928
133,847
Loss from discontinued operations
0
(282)
Net Income
174,928
133,565
Less: Net income attributable to noncontrolling interests
(8,931)
(3,304)
Net income attributable to Henry Schein, Inc.
$
165,997
$
130,261
Amounts attributable to Henry Schein, Inc.:
Continuing operations
$
165,997
$
130,543
Discontinued operations
0
(282)
Net income attributable to Henry Schein, Inc.
$
165,997
$
130,261
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic
$
1.17
$
0.91
Diluted
$
1.16
$
0.91
Loss per share from discontinued operations attributable to Henry Schein, Inc.:
Basic
$
0
$
0.00
Diluted
$
0
$
0.00
Earnings per share attributable to Henry Schein, Inc.:
Basic
$
1.17
$
0.91
Diluted
$
1.16
$
0.91
Weighted
-average common shares outstanding:
Basic
142,298
142,967
Diluted
143,398
143,095

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

 

2021

 

2020

 

2021

 

2020

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss)

 

$

163,977

 

$

(13,267)

 

$

338,905

 

$

120,298

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss), net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation gain (loss)

 

 

38,138

 

 

34,408

 

 

(343)

 

 

(54,904)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) from foreign currency hedging

 

 

 

 

 

 

 

 

 

 

 

 

 

 

activities

 

 

(1,751)

 

 

(4,989)

 

 

1,610

 

 

10,154

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized investment gain (loss)

 

 

3

 

 

2

 

 

(3)

 

 

(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Pension adjustment gain (loss)

 

 

35

 

 

(225)

 

 

842

 

 

499

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other comprehensive income (loss), net of tax

 

 

36,425

 

 

29,196

 

 

2,106

 

 

(44,258)

Comprehensive income

 

 

200,402

 

 

15,929

 

 

341,011

 

 

76,040

 

Comprehensive income attributable to noncontrolling

 

 

 

 

 

 

 

 

 

 

 

 

 

interests:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net (income) loss

 

 

(8,261)

 

 

2,470

 

 

(17,192)

 

 

(834)

 

 

Foreign currency translation (gain) loss

 

 

(6,899)

 

 

(799)

 

 

(801)

 

 

12,380

 

 

 

Comprehensive (income) loss attributable to noncontrolling

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

interests

 

 

(15,160)

 

 

1,671

 

 

(17,993)

 

 

11,546

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Comprehensive income attributable to Henry Schein, Inc.

 

$

185,242

 

$

17,600

 

$

323,018

 

$

87,586

See accompanying notes.

5


5

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS
OF COMPREHENSIVE INCOME
(in thousands)
(unaudited)
Three Months Ended
March 27,
March 28,
2021
2020
Net income
$
174,928
$
133,565
Other comprehensive loss, net of tax:
Foreign currency translation loss
(38,481)
(89,312)
Unrealized gain from foreign currency hedging activities
3,361
15,143
Unrealized investment loss
(6)
(9)
Pension adjustment gain
807
724
Other comprehensive loss, net of tax
(34,319)
(73,454)
Comprehensive income
140,609
60,111
Comprehensive (income) loss attributable to noncontrolling interests:
Net income
(8,931)
(3,304)
Foreign currency translation loss
6,098
13,179
Comprehensive (income) loss attributable to noncontrolling interests
(2,833)
9,875
Comprehensive income attributable to Henry Schein, Inc.
$
137,776
$
69,986
See accompanying notes.
6
HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT

OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Common Stock

Additional

 

 

Other

 

 

Total

 

 

$.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

 

 

Shares

 

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, March 27, 2021

141,310,113

$

1,413

$

0

$

3,493,060

$

(136,305)

$

638,562

$

3,996,730

Net income (excluding $6,980 attributable to Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

noncontrolling interests from continuing operations)

-

 

0

 

0

 

155,716

 

0

 

1,281

 

156,997

Foreign currency translation gain (excluding gain of $6,743

 

 

 

 

 

 

 

 

 

 

 

 

 

 

attributable to Redeemable noncontrolling interests)

-

 

0

 

0

 

0

 

31,239

 

156

 

31,395

Unrealized loss from foreign currency hedging activities,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

net of tax benefit of $687

-

 

0

 

0

 

0

 

(1,751)

 

0

 

(1,751)

Unrealized investment gain, net of tax of $1

-

 

0

 

0

 

0

 

3

 

0

 

3

Pension adjustment gain, net of tax benefit of $38

-

 

0

 

0

 

0

 

35

 

0

 

35

Dividends paid

-

 

0

 

0

 

0

 

0

 

(77)

 

(77)

Change in fair value of redeemable securities

-

 

0

 

(87,188)

 

0

 

0

 

0

 

(87,188)

Initial noncontrolling interests and adjustments related to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

business acquisitions

-

 

0

 

0

 

0

 

0

 

6,493

 

6,493

Repurchase and retirement of common stock

(1,542,315)

 

(15)

 

(14,992)

 

(97,545)

 

0

 

0

 

(112,552)

Stock-based compensation expense

17,916

 

0

 

17,364

 

0

 

0

 

0

 

17,364

Shares withheld for payroll taxes

(4,873)

 

0

 

(369)

 

0

 

0

 

0

 

(369)

Settlement of stock-based compensation awards

-

 

0

 

(399)

 

0

 

0

 

0

 

(399)

Transfer of charges in excess of capital

-

 

0

 

85,584

 

(85,584)

 

0

 

0

 

0

Balance, June 26, 2021

139,780,841

$

1,398

$

0

$

3,465,647

$

(106,779)

$

646,415

$

4,006,681

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Common Stock

Additional

 

 

Other

 

 

Total

 

 

$.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

 

 

Shares

 

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, March 28, 2020

142,433,360

$

1,424

$

17,565

$

3,183,236

$

(227,648)

$

631,215

$

3,605,792

Net loss (excluding loss of $1,678 attributable to Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

noncontrolling interests from continuing operations)

-

 

0

 

0

 

(10,797)

 

0

 

(792)

 

(11,589)

Foreign currency translation gain (excluding gain of $751

 

 

 

 

 

 

 

 

 

 

 

 

 

 

attributable to Redeemable noncontrolling interests)

-

 

0

 

0

 

0

 

33,609

 

48

 

33,657

Unrealized loss from foreign currency hedging activities,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

net of tax benefit of $1,744

-

 

0

 

0

 

0

 

(4,989)

 

0

 

(4,989)

Unrealized investment gain, net of tax of $1

-

 

0

 

0

 

0

 

2

 

0

 

2

Pension adjustment loss, net of tax benefit of $125

-

 

0

 

0

 

0

 

(225)

 

0

 

(225)

Dividends paid

-

 

0

 

0

 

0

 

0

 

(8)

 

(8)

Purchase of noncontrolling interests

-

 

0

 

0

 

0

 

0

 

(9)

 

(9)

Change in fair value of redeemable securities

-

 

0

 

(7,489)

 

0

 

0

 

0

 

(7,489)

Initial noncontrolling interests and adjustments related to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

business acquisitions

-

 

0

 

0

 

0

 

0

 

4

 

4

Stock-based compensation expense

7,033

 

0

 

5,156

 

0

 

0

 

0

 

5,156

Shares withheld for payroll taxes

(2,266)

 

0

 

(132)

 

0

 

0

 

0

 

(132)

Settlement of stock-based compensation awards

-

 

0

 

(273)

 

0

 

0

 

0

 

(273)

Separation of Animal Health business

-

 

0

 

1,648

 

0

 

0

 

0

 

1,648

Balance, June 27, 2020

142,438,127

$

1,424

$

16,475

$

3,172,439

$

(199,251)

$

630,458

$

3,621,545

(unaudited)

See accompanying notes.

6


Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 26, 2020
142,462,571
$
1,425
$
0
$
3,454,831
$
(108,084)
$
636,213
$
3,984,385
Net income (excluding $
7,053
attributable to Redeemable
noncontrolling interests from continuing operations)
-
0
0
165,997
0
1,878
167,875
Foreign currency translation loss (excluding loss of $
6,173
attributable to Redeemable noncontrolling interests)
-
0
0
0
(32,383)
75
(32,308)
Unrealized gain from foreign currency hedging activities,
net of tax of $
1,334
-
0
0
0
3,361
0
3,361
Unrealized investment loss, net of tax benefit of $
2
-
0
0
0
(6)
0
(6)
Pension adjustment gain, net of tax of $
219
-
0
0
0
807
0
807
Dividends paid
-
0
0
0
0
(77)
(77)
Change in fair value of redeemable securities
-
0
(45,520)
0
0
0
(45,520)
Initial noncontrolling interests and adjustments related to
business acquisitions
-
0
0
0
0
473
473
Repurchase and retirement of common stock
(1,325,242)
(13)
(12,250)
(76,396)
0
0
(88,659)
Stock-based compensation expense
281,645
3
12,787
0
0
0
12,790
Settlement of stock-based compensation awards
-
0
787
0
0
0
787
Shares withheld for payroll taxes
(108,861)
(2)
(7,176)
0
0
0
(7,178)
Transfer of charges in excess of
capital
-
0
51,372
(51,372)
0
0
0
Balance, March 27, 2021
141,310,113
$
1,413
$
0
$
3,493,060
$
(136,305)
$
638,562
$
3,996,730
Accumulated
Common Stock
Additional
Other
Total
$.01 Par Value
Paid-in
Retained
Comprehensive
Noncontrolling
Stockholders'
Shares
Amount
Capital
Earnings
Income / (Loss)
Interests
Equity
Balance, December 28, 2019
143,353,459
$
1,434
$
47,768
$
3,116,215
$
(167,373)
$
632,093
$
3,630,137
Cumulative impact of adopting new accounting standards
-
0
0
(412)
0
0
(412)
Net income (excluding $
2,839
attributable to Redeemable
noncontrolling interests from continuing operations)
-
0
0
130,261
0
465
130,726
Foreign currency translation loss (excluding loss of $
13,027
attributable to Redeemable noncontrolling interests)
-
0
0
0
(76,133)
(152)
(76,285)
Unrealized gain from foreign currency hedging activities,
net of tax of $
5,090
-
0
0
0
15,143
0
15,143
Unrealized investment loss, net of tax benefit of $
2
-
0
0
0
(9)
0
(9)
Pension adjustment gain, net of tax of $
324
-
0
0
0
724
0
724
Dividends paid
-
0
0
0
0
(499)
(499)
Purchase of noncontrolling interests
-
0
(1,597)
0
0
(692)
(2,289)
Change in fair value of redeemable securities
-
0
13,072
0
0
0
13,072
Repurchase and retirement of common stock
(1,200,000)
(12)
(10,949)
(62,828)
0
0
(73,789)
Stock-based compensation credit
507,410
5
(17,519)
0
0
0
(17,514)
Shares withheld for payroll taxes
(227,509)
(3)
(13,871)
0
0
0
(13,874)
Settlement of stock-based compensation awards
-
0
660
0
0
0
660
Separation of Animal Health business
-
0
1
0
0
0
1
Balance, March 28, 2020
142,433,360
$
1,424
$
17,565
$
3,183,236
$
(227,648)
$
631,215
$
3,605,792

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY

(in thousands, except share and per share data)

(unaudited)

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Common Stock

Additional

 

 

Other

 

 

Total

 

 

$.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

 

 

Shares

 

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, December 26, 2020

142,462,571

$

1,425

$

0

$

3,454,831

$

(108,084)

$

636,213

$

3,984,385

Net income (excluding $14,033 attributable to Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

noncontrolling interests from continuing operations)

-

 

0

 

0

 

321,713

 

0

 

3,159

 

324,872

Foreign currency translation gain (loss) (excluding gain of $570

 

 

 

 

 

 

 

 

 

 

 

 

 

 

attributable to Redeemable noncontrolling interests)

-

 

0

 

0

 

0

 

(1,144)

 

231

 

(913)

Unrealized gain from foreign currency hedging activities,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

net of tax of $647

-

 

0

 

0

 

0

 

1,610

 

0

 

1,610

Unrealized investment loss, net of tax benefit of $1

-

 

0

 

0

 

0

 

(3)

 

0

 

(3)

Pension adjustment gain, net of tax of $181

-

 

0

 

0

 

0

 

842

 

0

 

842

Dividends paid

-

 

0

 

0

 

0

 

0

 

(154)

 

(154)

Change in fair value of redeemable securities

-

 

0

 

(132,708)

 

0

 

0

 

0

 

(132,708)

Initial noncontrolling interests and adjustments related to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

business acquisitions

-

 

0

 

0

 

0

 

0

 

6,966

 

6,966

Repurchase and retirement of common stock

(2,867,557)

 

(29)

 

(27,241)

 

(173,941)

 

0

 

0

 

(201,211)

Stock-based compensation expense

299,561

 

3

 

30,151

 

0

 

0

 

0

 

30,154

Shares withheld for payroll taxes

(113,734)

 

(1)

 

(7,546)

 

0

 

0

 

0

 

(7,547)

Settlement of stock-based compensation awards

0

 

0

 

388

 

0

 

0

 

0

 

388

Transfer of charges in excess of capital

-

 

0

 

136,956

 

(136,956)

 

0

 

0

 

0

Balance, June 26, 2021

139,780,841

$

1,398

$

0

$

3,465,647

$

(106,779)

$

646,415

$

4,006,681

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

Common Stock

Additional

 

 

Other

 

 

Total

 

 

$.01 Par Value

Paid-in

Retained

Comprehensive

Noncontrolling

Stockholders'

 

 

Shares

 

Amount

Capital

Earnings

Income / (Loss)

Interests

Equity

Balance, December 28, 2019

143,353,459

$

1,434

$

47,768

$

3,116,215

$

(167,373)

$

632,093

$

3,630,137

Cumulative impact of adopting new accounting standards

-

 

0

 

0

 

(412)

 

0

 

0

 

(412)

Net income (excluding $1,161 attributable to Redeemable

 

 

 

 

 

 

 

 

 

 

 

 

 

 

noncontrolling interests from continuing operations)

-

 

0

 

0

 

119,464

 

0

 

(327)

 

119,137

Foreign currency translation loss (excluding loss of $12,276

 

 

 

 

 

 

 

 

 

 

 

 

 

 

attributable to Redeemable noncontrolling interests)

-

 

0

 

0

 

0

 

(42,524)

 

(104)

 

(42,628)

Unrealized gain from foreign currency hedging activities,

 

 

 

 

 

 

 

 

 

 

 

 

 

 

net of tax of $3,346

-

 

0

 

0

 

0

 

10,154

 

0

 

10,154

Unrealized investment loss, net of tax benefit of $1

-

 

0

 

0

 

0

 

(7)

 

0

 

(7)

Pension adjustment gain, net of tax of $199

-

 

0

 

0

 

0

 

499

 

0

 

499

Dividends paid

-

 

0

 

0

 

0

 

0

 

(507)

 

(507)

Purchase of noncontrolling interests

-

 

0

 

(1,597)

 

0

 

0

 

(701)

 

(2,298)

Change in fair value of redeemable securities

-

 

0

 

5,583

 

0

 

0

 

0

 

5,583

Initial noncontrolling interests and adjustments related to

 

 

 

 

 

 

 

 

 

 

 

 

 

 

business acquisitions

-

 

0

 

0

 

0

 

0

 

4

 

4

Repurchase and retirement of common stock

(1,200,000)

 

(12)

 

(10,949)

 

(62,828)

 

0

 

0

 

(73,789)

Stock-based compensation expense (credit)

514,443

 

5

 

(12,363)

 

0

 

0

 

0

 

(12,358)

Shares withheld for payroll taxes

(229,775)

 

(3)

 

(14,003)

 

0

 

0

 

0

 

(14,006)

Settlement of stock-based compensation awards

0

 

0

 

387

 

0

 

0

 

0

 

387

Separation of Animal Health business

-

 

0

 

1,649

 

0

 

0

 

0

 

1,649

Balance, June 27, 2020

142,438,127

$

1,424

$

16,475

$

3,172,439

$

(199,251)

$

630,458

$

3,621,545

See accompanying notes.

7


7

HENRY SCHEIN, INC.

CONSOLIDATED STATEMENTS

OF CASH FLOWS

(in thousands)

(unaudited)

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 26,

 

June 27,

 

 

 

 

 

 

2021

 

2020

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income

 

$

338,905

 

$

120,298

 

Income from discontinued operations

 

 

0

 

 

303

 

Income from continuing operations

 

 

338,905

 

 

119,995

 

Adjustments to reconcile net income to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

 

Depreciation and amortization

 

 

99,278

 

 

93,946

 

 

 

Impairment charge on intangible assets

 

 

0

 

 

2,149

 

 

 

Stock-based compensation expense (credit)

 

 

30,154

 

 

(12,358)

 

 

 

Provision for (benefit from) losses on trade and other accounts receivable

 

 

(4,072)

 

 

28,758

 

 

 

Provision (benefit from) for deferred income taxes

 

 

5,705

 

 

(32,871)

 

 

 

Equity in earnings of affiliates

 

 

(12,201)

 

 

(4,145)

 

 

 

Distributions from equity affiliates

 

 

10,747

 

 

4,220

 

 

 

Changes in unrecognized tax benefits

 

 

(6,286)

 

 

1,380

 

 

 

Other

 

 

3,429

 

 

227

 

 

 

Changes in operating assets and liabilities, net of acquisitions:

 

 

 

 

 

 

 

 

 

 

Accounts receivable

 

 

101,619

 

 

99,672

 

 

 

 

Inventories

 

 

(123,758)

 

 

13,700

 

 

 

 

Other current assets

 

 

(85,979)

 

 

(188,616)

 

 

 

 

Accounts payable and accrued expenses

 

 

(135,815)

 

 

(138,900)

Net cash provided by (used in) operating activities from continuing operations

 

 

221,726

 

 

(12,843)

Net cash provided by operating activities from discontinued operations

 

 

0

 

 

573

Net cash provided by (used in) operating activities

 

 

221,726

 

 

(12,270)

 

 

 

 

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Purchases of fixed assets

 

 

(31,812)

 

 

(30,588)

 

Payments related to equity investments and business

 

 

 

 

 

 

 

 

acquisitions, net of cash acquired

 

 

(295,652)

 

 

(37,725)

 

Proceeds from sale of equity investment

 

 

0

 

 

12,000

 

Payments for loan to affiliate

 

 

(2,021)

 

 

(1,729)

 

Other

 

 

(11,634)

 

 

(11,599)

Net cash used in investing activities from continuing operations

 

 

(341,119)

 

 

(69,641)

Net cash used in investing activities from discontinued operations

 

 

0

 

 

0

Net cash used in investing activities

 

 

(341,119)

 

 

(69,641)

 

 

 

 

 

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Net change in bank borrowings

 

 

(5,381)

 

 

479,702

 

Proceeds from issuance of long-term debt

 

 

200,000

 

 

501,421

 

Principal payments for long-term debt

 

 

(120,326)

 

 

(609,580)

 

Debt issuance costs

 

 

(199)

 

 

(3,655)

 

Payments for repurchases of common stock

 

 

(201,211)

 

 

(73,789)

 

Payments for taxes related to shares withheld for employee taxes

 

 

(7,359)

 

 

(13,713)

 

Distributions to noncontrolling shareholders

 

 

(3,789)

 

 

(3,466)

 

Acquisitions of noncontrolling interests in subsidiaries

 

 

(1,130)

 

 

(14,934)

 

Proceeds from Henry Schein Animal Health Business

 

 

0

 

 

64

Net cash provided by (used in) financing activities from continuing operations

 

 

(139,395)

 

 

262,050

Net cash used in financing activities from discontinued operations

 

 

0

 

 

(573)

Net cash provided by (used in) financing activities

 

 

(139,395)

 

 

261,477

Effect of exchange rate changes on cash and cash equivalents from continuing operations

 

 

4,831

 

 

10,447

Effect of exchange rate changes on cash and cash equivalents from discontinued operations

 

 

0

 

 

0

Net change in cash and cash equivalents from continuing operations

 

 

(253,957)

 

 

190,013

Net change in cash and cash equivalents from discontinued operations

 

 

0

 

 

0

Cash and cash equivalents, beginning of period

 

 

421,185

 

 

106,097

Cash and cash equivalents, end of period

 

$

167,228

 

$

296,110

(unaudited)

See accompanying notes.

8


Three Months Ended
March 27,
March 28,
2021
2020
Cash flows from operating activities:
Net income
$
174,928
$
133,565
Loss from discontinued operations
0
(282)
Income from continuing operations
174,928
133,847
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
49,363
46,983
Impairment charge on intangible assets
0
2,000
Stock-based compensation (credit) expense
12,790
(17,514)
Provision for (benefit from) losses on trade and other accounts receivable
(2,696)
14,543
Provision for deferred income taxes
11,171
2,645
Equity in earnings of affiliates
(5,878)
(2,734)
Distributions from equity affiliates
5,139
2,413
Changes in unrecognized tax benefits
2,804
(1,575)
Other
35
(13,924)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable
118,795
(1,283)
Inventories
(78,085)
73,038
Other current assets
(45,310)
(22,002)
Accounts payable and accrued expenses
(179,725)
(137,680)
Net cash provided by operating activities from continuing operations
63,331
78,757
Net cash used in operating activities from discontinued operations
0
(282)
Net cash provided by operating activities
63,331
78,475
Cash flows from investing activities:
Purchases of fixed assets
(13,843)
(23,008)
Payments related to equity investments and business
acquisitions, net of cash acquired
(204,027)
(37,947)
Proceeds from sale of equity investment
0
12,000
Repayments from loan to affiliate
139
1,137
Other
(5,513)
(5,787)
Net cash used in investing activities from continuing operations
(223,244)
(53,605)
Net cash used in investing activities from discontinued operations
0
0
Net cash used in investing activities
(223,244)
(53,605)
Cash flows from financing activities:
Net change in bank borrowings
(241)
358,639
Proceeds from issuance of long-term debt
0
250,000
Principal payments for long-term debt
(17,781)
(8,478)
Debt issuance costs
(85)
(58)
Payments for repurchases of common stock
(88,659)
(73,789)
Payments for taxes related to shares withheld for employee taxes
(6,158)
(13,155)
Distributions to noncontrolling shareholders
(6,520)
(3,664)
Acquisitions of noncontrolling interests in subsidiaries
0
(14,925)
Payments to Henry Schein Animal Health Business
0
(2,962)
Net cash provided by (used in) financing activities from continuing operations
(119,444)
491,608
Net cash provided by financing activities from discontinued operations
0
282
Net cash provided by (used in) financing activities
(119,444)
491,890
Effect of exchange rate changes on cash and cash equivalents from continuing operations
2,710
(5,489)
Effect of exchange rate changes on cash and cash equivalents from discontinued operations
0
0
Net change in cash and cash equivalents from continuing operations
(276,647)
511,271
Net change in cash and cash equivalents from discontinued operations
0
0
Cash and cash equivalents, beginning of period
421,185
106,097
Cash and cash equivalents, end of period
$
144,538
$
617,368

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited

)
8

Note 1

Basis of Presentation

Our consolidated financial statements include our accounts, as well

as those of our wholly-owned and majority-
ownedmajority-owned subsidiaries.
Certain prior period amounts have been reclassified to conform
to the current period
presentation.

Our accompanying unaudited consolidated financial statements have been

prepared in accordance with accounting
principles generally accepted in the United States (“U.S. GAAP”) for interim
financial information and with the
instructions to Form 10-Q and Article 10 of Regulation S-X.
Accordingly, they do not include all of the
information and footnote disclosures required by U.S. GAAP for
complete financial statements.

We consolidate a Variable Interest Entity (“VIE”) where we hold a variable interest and are the primary

beneficiary.
The VIE is a trade accounts receivable securitization.
We are the primary beneficiary because we
have the power to direct activities that most significantly affect the economic performance
and have the obligation
to absorb the majority of the losses or benefits.
The results of operations and financial position of this VIE
are
included in our consolidated financial statements.

For the consolidated VIE, the trade accounts receivable transferred

to the VIE are pledged as collateral to the
related debt.
The creditors have recourse to us for losses on these trade accounts receivable.
At March 27,June 26, 2021
and December 26, 2020,
there were no0 trade accounts receivable that were restricted to settle obligations of this
VIE,
nor 0r were there liabilities of the VIE where the creditors have recourse to us.

The consolidated financial statements reflect all adjustments considered

necessary for a fair presentation of the
consolidated results of operations and financial position for the interim periods
presented.
All such adjustments are
of a normal recurring nature.
These unaudited interim consolidated financial statements should
be read in
conjunction with the audited consolidated financial statements and notes
to the consolidated financial statements
contained in our Annual Report on Form 10-K for the year ended December
26, 2020.

The preparation of financial statements in conformity with accounting principles

generally accepted in the United
States
requires us to make estimates and assumptions that affect the reported amounts of assets
and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of
revenues and expenses during the reporting period.
Actual results could differ from those estimates.
The results of
operations for the threesix months ended March 27,June 26, 2021 are not necessarily
indicative of the results to be expected
for any other interim period or for the year ending December 25, 2021.

In March 2020, the World Health Organization declared the Novel Coronavirus Disease 2019 (“COVID-19”) a

pandemic. The COVID-19 pandemic negatively impacted the global economy, disrupted global supply chains and
created significant volatility and disruption of global financial markets. In response,
many countries implemented
business closures and restrictions, stay-at-home and social distancing ordinances
and similar measures to combat
the pandemic, which significantly impacted global business and dramatically
reduced demand for dental products
and certain medical products in the second quarter of 2020.
Demand increased in the second half of 2020 and has
continued into the first quarterhalf of 2021, resulting in growth over the
prior year driven by sales of personal
protective equipment (PPE) and COVID-19 related products.

9


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
9

Our consolidated financial statements reflect estimates and assumptions

made by us that affect, among other things,
our goodwill, long-lived asset and definite-lived intangible asset valuation;
inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income
taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; vendor
rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus
plans; and pension plan
assumptions. Due to the significant uncertainty surrounding the
future impact of COVID-19, our judgments
regarding estimates and impairments could change in the future. In
addition, the impact of COVID-19 had a
material adverse effect on our business, results of operations and cash flows, primarily
in the second quarter of
2020. In the latter half of the second quarter of 2020,
dental and medical practices began to re-open worldwide, and
continued to do so during the second half of 2020.
During the first quarterhalf of 2021, patient traffic levels returned to
levels approaching pre-pandemic levels, although certain regions in the U.S.
and internationally are experiencing an
increase in COVID-19 cases.levels. There is an ongoing risk that the COVID-19
pandemic may again have a material
adverse effect on our business, results of operations and cash flows and may result
in a material adverse effect on
our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at
this time.

Note 2 – Critical Accounting Policies, Accounting Pronouncements Adopted and Recently Issued Accounting

Standards

Critical Accounting Policies

There have been no material changes in our critical accounting policies during

the threesix months ended March 27,
June 26, 2021, as compared to the critical accounting policies described in Item
8 to the consolidated financial statements
included in our Annual Report on Form 10-K for the year ended December
26, 2020, except as follows:

Accounting Pronouncements Adopted

In

December 2019
, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update
(“ASU”) No. 2019-12, “Income Taxes” (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-
12”2019-12”).
ASU 2019-12 will simplify the accounting for income taxes
by removing certain exceptions to the general
principles in Topic 740.
The amendments also improve consistent application
of and simplify U.S. GAAP for other
areas of Topic 740 by clarifying and amending existing guidance.
Our
adoption
of ASU 2019 - 122019-12 did not have a
material impact on our consolidated financial statements.

Recently Issued Accounting Standards

In August 2020, the FASB issued ASU No. 2020-06, “Debt—Debt with Conversion and Other Options” (Subtopic

470-20) and “Derivatives and Hedging— in Entity’s Own Equity” (Subtopic 815-40): Accounting for Convertible
Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”).
ASU 2020-06 simplifies the accounting
for convertible instruments.
In addition to eliminating certain accounting models, this ASU
includes improvements
to the disclosures for convertible instruments and earnings-per-share (EPS) guidance and
amends the guidance for
the derivatives scope exception for contracts in an entity’s own equity.
ASU 2020-06 is effective for fiscal years
beginning after December 15, 2021.
We do not expect that the requirements of this ASU will have a material
impact on our consolidated financial statements.

10


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
10

Note 3 – Revenue from Contracts with Customers

Revenue is recognized in accordance with policies disclosed in Item 8 of our

Annual Report on Form 10-K for
the year ended December 26, 2020.

Disaggregation of Revenue

The following table disaggregates our revenue by segment and geography:

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

June 26, 2021

 

June 26, 2021

 

 

 

 

North America

 

International

 

Global

 

North America

 

International

 

Global

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Health care distribution

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dental

$

1,127,607

 

$

782,737

 

$

1,910,344

 

$

2,172,390

 

$

1,526,882

 

$

3,699,272

 

Medical

 

877,773

 

 

27,055

 

 

904,828

 

 

1,842,900

 

 

54,965

 

 

1,897,865

 

 

Total health care distribution

 

2,005,380

 

 

809,792

 

 

2,815,172

 

 

4,015,290

 

 

1,581,847

 

 

5,597,137

Technology and value-added services

 

129,897

 

 

22,154

 

 

152,051

 

 

251,834

 

 

43,213

 

 

295,047

 

 

Total revenues

$

2,135,277

 

$

831,946

 

$

2,967,223

 

$

4,267,124

 

$

1,625,060

 

$

5,892,184

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

June 27, 2020

 

June 27, 2020

 

 

 

 

North America

 

International

 

Global

 

North America

 

International

 

Global

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Health care distribution

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dental

$

515,946

 

$

425,346

 

$

941,292

 

$

1,404,318

 

$

1,012,050

 

$

2,416,368

 

Medical

 

596,588

 

 

21,222

 

 

617,810

 

 

1,374,616

 

 

43,882

 

 

1,418,498

 

 

Total health care distribution

 

1,112,534

 

 

446,568

 

 

1,559,102

 

 

2,778,934

 

 

1,055,932

 

 

3,834,866

Technology and value-added services

 

92,927

 

 

12,300

 

 

105,227

 

 

206,425

 

 

30,767

 

 

237,192

Total excluding Corporate TSA revenues (1)

 

1,205,461

 

 

458,868

 

 

1,664,329

 

 

2,985,359

 

 

1,086,699

 

 

4,072,058

Corporate TSA revenues (1)

 

0

 

 

20,070

 

 

20,070

 

 

0

 

 

41,212

 

 

41,212

 

 

Total revenues

$

1,205,461

 

$

478,938

 

$

1,684,399

 

$

2,985,359

 

$

1,127,911

 

$

4,113,270

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended
March 27, 2021
North America
International
Global
Revenues:
Health care distribution
Dental
$
1,044,783
744,145
1,788,928
Medical
965,127
27,910
993,037
Total health care distribution
2,009,910
772,055
2,781,965
Technology
and value-added services
121,937
21,059
142,996
Total revenues
$
2,131,847
$
793,114
$
2,924,961
Three Months Ended
March 28, 2020
North America
International
Global
Revenues:
Health care distribution
Dental
$
888,372
586,704
1,475,076
Medical
778,028
22,660
800,688
Total health care distribution
1,666,400
609,364
2,275,764
Technology
and value-added services
113,498
18,467
131,965
Total excluding
Corporate TSA revenues

(1)

1,779,898
627,831
2,407,729
Corporate TSA revenues
(1)
0
21,142
21,142
Total revenues
$
1,779,898
$
648,973
$
2,428,871
(1)
Corporate TSA revenues represents sales of certain animal health products to Covetrus under the transition services agreement
entered into in connection with the Animal Health Spin-off, which ended in December 2020.
See
for further information.

At December 26, 2020, the current portion of contract liabilities of $

71.5
$71.5 million was reported in Accrued
expenses: Other, and $
8.2
$8.2 million related to non-current contract liabilities werewas reported in Other liabilities.
During the threesix months ended March 27,June 26, 2021, we recognized in revenue
$
32.9
$47.1 million of the amounts that were
previously deferred at December 26, 2020.
At March 27,June 26, 2021, the current and non-current portion of contract
liabilities were $
73.7
$70.9 million and $
9.5
$9.0 million, respectively.

11


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
11

Note 4

Segment Data

We conduct our business through

2
reportable segments: (i) health care distribution and (ii) technology
and
value-added services.
These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental

and medical operating segments.
This
segment distributes consumable products, small equipment, laboratory products,
large equipment, equipment repair
services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control
products and vitamins.
Our global dental group serves office-based dental practitioners, dental laboratories, schools
and other institutions.
Our global medical group serves office-based medical practitioners, ambulatory
surgery
centers, other alternate-care settings and other institutions.
Our global dental and medical groups serve
practitioners in
31
32 countries worldwide.

Our global technology and value-added services group provides software,

technology and other value-added
services to health care practitioners.
Our technology group offerings include practice management software
systems for dental and medical practitioners.
Our value-added practice solutions include financial services on a
non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education
services for practitioners.

The following tables present information about our reportable and operating segments:

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

 

2021

 

2020

 

2021

 

2020

Net Sales:

 

 

 

 

 

 

 

 

 

 

 

 

 

Health care distribution (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dental

 

$

1,910,344

 

$

941,292

 

$

3,699,272

 

$

2,416,368

 

 

Medical

 

 

904,828

 

 

617,810

 

 

1,897,865

 

 

1,418,498

 

 

Total health care distribution

 

 

2,815,172

 

 

1,559,102

 

 

5,597,137

 

 

3,834,866

 

Technology and value-added services (2)

 

 

152,051

 

 

105,227

 

 

295,047

 

 

237,192

 

 

Total excluding Corporate TSA revenue

 

 

2,967,223

 

 

1,664,329

 

 

5,892,184

 

 

4,072,058

 

Corporate TSA revenues (3)

 

 

0

 

 

20,070

 

 

0

 

 

41,212

 

 

Total

 

$

2,967,223

 

$

1,684,399

 

$

5,892,184

 

$

4,113,270

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

segments:
Three Months Ended
March 27,
March 28,
2021
2020
Net Sales:
Health care distribution

(1)

Dental
$
1,788,928
$
1,475,076
Medical
993,037
800,688
Total health care distribution
2,781,965
2,275,764
Technology
and value-added services
(2)
142,996
131,965
Total excluding
Corporate TSA revenue
2,924,961
2,407,729
Corporate TSA revenues
(3)
0
21,142
Total
$
2,924,961
$
2,428,871
(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic
pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment
and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.

(3)

Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with the Animal Health Spin-off, which ended in December 2020.
See
for further information.

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

 

2021

 

2020

 

2021

 

2020

Operating Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

Health care distribution

 

$

181,761

 

$

(25,348)

 

$

379,693

 

$

122,819

 

Technology and value-added services

 

 

28,585

 

 

17,915

 

 

60,581

 

 

43,613

 

 

Total

 

$

210,346

 

$

(7,433)

 

$

440,274

 

$

166,432

information.

12


Three Months Ended
March 27,
March 28,
2020
2020
Operating Income:
Health care distribution
$
197,932
$
148,167
Technology
and value-added services
31,996
25,698
Total
$
229,928
$
173,865

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
12

Note 5 – Debt

Bank Credit Lines

Bank credit lines consisted of the following:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Revolving credit agreement

 

$

0

 

$

0

Other short-term bank credit lines

 

 

72,105

 

 

73,366

Total

 

$

72,105

 

$

73,366

March 27,
December 26,
2021
2020
Revolving credit agreement
$
0
$
0
Other short-term bank credit lines
67,415
73,366
Total
$
67,415
$
73,366

Revolving Credit Agreement

On

April 18, 2017,
, we entered into a $
750
$750 million revolving credit agreement (the “Credit Agreement”), which
matures in
April 2022
.
The interest rate is based on the USD LIBOR
plus a spread based on our leverage ratio at
the end of each financial reporting quarter.
We expect most LIBOR rates to be discontinued immediately after
December 31, 2021, while the remaining LIBOR rates will be discontinued
immediately after June 30, 2023, which
will require an amendment to our debt agreements to reflect a new
reference rate. We do not expect the
discontinuation of LIBOR as a reference rate in our debt agreements
to have a material adverse effect on our
financial position or to materially affect our interest expense.
The Credit Agreement also requires, among other
things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary
representations, warranties and affirmative covenants as well as customary negative
covenants, subject to
negotiated exceptions, on liens, indebtedness, significant corporate changes
(including (including mergers), dispositions and
certain restrictive agreements.
As of March 27,June 26, 2021, and December 26, 2020, we had no borrowings
on under this
revolving credit facility.
As of March 27,June 26, 2021, and December 26, 2020, there were $
9.3
million and $
9.5
$9.5 million
of letters of credit, respectively, provided to third parties under the credit facility.

On April 17, 2020, we amended the Credit Agreement to, among other

things, (i) modify the financial covenant
from being based on total leverage ratio to net leverage ratio, (ii) adjust the
pricing grid to reflect the net leverage
ratio calculation, and (iii) increase the maximum maintenance leverage ratio
through March 31, 2021.

364-Day Credit Agreement

On March 4, 2021, we repaid the outstanding obligations and terminated

the lender commitments under our $
700
$700 million
364
-day 364-day credit agreement which was entered into on
April 17, 2020
.
2020. This facility was originally scheduled
to mature on
April 16, 2021
.
2021.

Other Short-Term Credit

Lines

As of March 27,June 26, 2021 and December 26, 2020, we had various other short-term

bank credit lines available, of
which $
67.4
$72.1 million and $
73.4
$73.4 million, respectively, were outstanding.
At March 27,June 26, 2021 and December 26,
2020, borrowings under all of these credit lines had a weighted average
interest rate of 5.98% and 4.14%, respectively.

4.52

13


% and
4.14
%,
respectively.

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
13

Long-term debt

Long-term debt consisted of the following:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Private placement facilities

 

$

706,332

 

$

613,498

Note payable

 

 

0

 

 

1,554

Various collateralized and uncollateralized loans payable with interest,

 

 

 

 

 

 

 

in varying installments through 2023 at interest rates

 

 

 

 

 

 

 

ranging from 2.45% to 4.27% at June 26, 2021 and

 

 

 

 

 

 

 

ranging from 2.62% to 4.27% at December 26, 2020

 

 

4,293

 

 

4,596

Finance lease obligations (see Note 6)

 

 

5,701

 

 

5,961

 

Total

 

 

716,326

 

 

625,609

Less current maturities

 

 

(9,839)

 

 

(109,836)

 

Total long-term debt

 

$

706,487

 

$

515,773

March 27,
December 26,
2021
2020
Private placement facilities
$
606,355
$
613,498
Note payable
0
1,554
Various
collateralized and uncollateralized loans payable with interest,
in varying installments through
2023
at interest rates
ranging from
2.45
% to
4.27
% at March 27, 2021 and
ranging from
2.62
% to
4.27
% at December 26, 2020
5,969
4,596
Finance lease obligations (see Note 7)
5,313
5,961
Total
617,637
625,609
Less current maturities
(111,176)
(109,836)
Total long-term debt
$
506,461
$
515,773

Private Placement Facilities

Our private placement facilities, with

3
insurance companies, have a total facility amount of $
1
$1 billion, and are
available on an uncommitted basis at fixed rate economic terms to be agreed upon
at the time of issuance, from
time to time through
June 23, 2023
.
2023. The facilities allow us to issue senior promissory notes to the
lenders at a fixed
rate based on an agreed upon spread over applicable treasury notes at
the time of issuance.
The term of each
possible issuance will be selected by us and can range from
five
to
15
years (with an average life no longer than
12
years).
The proceeds of any issuances under the facilities will be used
for general corporate purposes, including
working capital and capital expenditures, to refinance existing indebtedness
and/or to fund potential acquisitions.
The agreements provide, among other things, that we maintain
certain maximum leverage ratios, and contain
restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal
of assets and certain changes in
ownership.
These facilities contain make-whole provisions in the event that we
pay off the facilities prior to the
applicable due dates.

On March 5, 2021, we amended the private placement facilities to, among other things, (a) modify the financial

covenant from being based on a net leverage ratio to a total leverage ratio and (b) restore the maximum
maintenance total leverage ratio to 3.25x and remove the 1.00% interest rate increase triggered if the net leverage
ratio were to exceed 3.0x.

14


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
14

The components of our private placement facility borrowings as

of March 27,June 26, 2021 are presented in the following
table (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Amount of

 

 

 

 

 

 

 

Borrowing

 

Borrowing

 

 

Date of Borrowing

 

Outstanding

 

Rate

 

Due Date

January 20, 2012 (1)

 

$

7,143

 

3.09

%

 

January 20, 2022

January 20, 2012

 

 

50,000

 

3.45

 

 

January 20, 2024

December 24, 2012

 

 

50,000

 

3.00

 

 

December 24, 2024

June 16, 2017

 

 

100,000

 

3.42

 

 

June 16, 2027

September 15, 2017

 

 

100,000

 

3.52

 

 

September 15, 2029

January 2, 2018

 

 

100,000

 

3.32

 

 

January 2, 2028

September 2, 2020

 

 

100,000

 

2.35

 

 

September 2, 2030

June 2, 2021

 

 

100,000

 

2.48

 

 

June 2, 2031

June 2, 2021

 

 

100,000

 

2.58

 

 

June 2, 2033

Less: Deferred debt issuance costs

 

 

(811)

 

 

 

 

 

 

 

$

706,332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

Amount of
Borrowing
Borrowing
Date of Borrowing
Outstanding
Rate
Due Date
January 20, 2012
(1)
$
7,143
3.09
%
January 20, 2022
January 20, 2012
50,000
3.45
January 20, 2024
December 24, 2012
50,000
3.00
December 24, 2024
June 2, 2014
100,000
3.19
June 2, 2021
June 16, 2017
100,000
3.42
June 16, 2027
September 15, 2017
100,000
3.52
September 15, 2029
January 2, 2018
100,000
3.32
January 2, 2028
September 2, 2020
100,000
2.35
September 2, 2030
Less: Deferred debt issuance costs
(788)
$
606,355
(1)
Annual
repayments of approximately $
7.1
million for this borrowing commenced on
January 20, 2016
.

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts

receivable that is structured as an asset-backed securitization program with pricing
committed for up to
three years
.
years. Our current facility, which has a purchase limit of $
350
$350 million, was scheduled to expire on
April 29, 2022
.
2022. On
June 22, 2020, the expiration date for this facility was extended to
June 12, 2023
and was amended to adjust certain
covenant levels for 2020.
As of March 27,June 26, 2021 and December 26, 2020, there were
0
borrowings outstanding
under this securitization facility.
At March 27,June 26, 2021, the interest rate on borrowings under this
facility was based
on the asset-backed commercial paper rate of
0.18
% 0.14% plus
0.95
% 0.95%, for a combined rate of
1.13
% 1.09%.
At December 26,
2020, the interest rate on borrowings under this facility was based
on the asset-backed commercial paper rate of
0.22
% 0.22% plus
0.95
% 0.95%, for a combined rate of
1.17
% 1.17%.

If our accounts receivable collection pattern changes due to customers either

paying late or not making payments,
our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of

25
to
45
basis points depending upon program utilization.

15


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited

)
15

Note 6 – Leases

Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles,

and certain equipment.
Our leases have remaining terms of less than
one year
to approximately
15 years,
, some of
which
may include options to extend the leases for up to 10 years
.
years. The components of lease expense were as follows:

 

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

 

 

2021

 

2020

 

2021

 

2020

 

Operating lease cost: (1)

 

$

25,840

 

$

21,991

 

$

48,946

 

$

44,070

 

Finance lease cost:

 

 

 

 

 

 

 

 

 

 

 

 

 

Amortization of right-of-use assets

 

 

516

 

 

282

 

 

1,120

 

 

714

 

Interest on lease liabilities

 

 

27

 

 

20

 

 

53

 

 

57

 

Total finance lease cost

 

$

543

 

$

302

 

$

1,173

 

$

771

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1)

Includes variable lease expenses.

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental balance sheet information related to leases is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 26,

 

December 26,

 

 

 

 

 

 

2021

 

2020

 

Operating Leases:

 

 

 

 

 

 

 

Operating lease right-of-use assets

 

$

301,440

 

$

288,847

 

 

 

 

 

 

 

 

 

 

 

 

Current operating lease liabilities

 

 

75,008

 

 

64,716

 

Non-current operating lease liabilities

 

 

243,232

 

 

238,727

 

 

Total operating lease liabilities

 

$

318,240

 

$

303,443

 

 

 

 

 

 

 

 

 

 

 

 

Finance Leases:

 

 

 

 

 

 

 

Property and equipment, at cost

 

$

11,443

 

$

10,683

 

Accumulated depreciation

 

 

(5,170)

 

 

(4,277)

 

Property and equipment, net of accumulated depreciation

 

$

6,273

 

$

6,406

 

 

 

 

 

 

 

 

 

 

 

 

Current maturities of long-term debt

 

$

2,420

 

$

2,420

 

Long-term debt

 

 

3,281

 

 

3,541

 

 

Total finance lease liabilities

 

$

5,701

 

$

5,961

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Remaining Lease Term in Years:

 

 

 

 

 

 

 

 

Operating leases

 

 

7.1

 

 

7.5

 

 

Finance leases

 

 

4.0

 

 

4.3

 

 

 

 

 

 

 

 

 

 

 

 

Weighted Average Discount Rate:

 

 

 

 

 

 

 

 

Operating leases

 

 

2.6

%

 

2.8

%

 

Finance leases

 

 

1.8

%

 

1.9

%

follows:

16


Three Months Ended
March 27,
March 28,
2021
2020
Operating lease cost:
(1)
$
23,106
$
22,079
Finance lease cost:
Amortization of right-of-use assets
604
432
Interest on lease liabilities
26
37
Total finance
lease cost
$
630
$
469
(1)
Includes variable lease expenses.
Supplemental balance sheet information related to leases is as follows:
March 27,
December 26,
2021
2020
Operating Leases:
Operating lease right-of-use assets
$
301,759
$
288,847
Current operating lease liabilities
68,580
64,716
Non-current operating lease liabilities
248,624
238,727
Total operating lease liabilities
$
317,204
$
303,443
Finance Leases:
Property and equipment, at cost
$
10,388
$
10,683
Accumulated depreciation
(4,607)
(4,277)
Property and equipment, net of accumulated depreciation
$
5,781
$
6,406
Current maturities of long-term debt
$
2,256
$
2,420
Long-term debt
3,057
3,541
Total finance
lease liabilities
$
5,313
$
5,961
Weighted Average
Remaining Lease Term in
Years:
Operating leases
7.4
7.5
Finance leases
4.2
4.3
Weighted Average
Discount Rate:
Operating leases
2.6
%
2.8
%
Finance leases
1.9
%
1.9
%

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Supplemental cash flow information related to leases is as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

June 26,

 

June 27,

 

 

 

 

 

 

2021

 

2020

 

Cash paid for amounts included in the measurement of lease liabilities:

 

 

 

 

 

 

 

 

Operating cash flows for operating leases

 

$

39,988

 

$

38,579

 

 

Operating cash flows for finance leases

 

 

47

 

 

50

 

 

Financing cash flows for finance leases

 

 

1,407

 

 

947

 

Right-of-use assets obtained in exchange for lease obligations:

 

 

 

 

 

 

 

 

Operating leases

 

$

49,226

 

$

14,926

 

 

Finance leases

 

 

1,244

 

 

1,814

 

Maturities of lease liabilities are as follows:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

June 26, 2021

 

 

 

 

 

 

 

Operating

 

 

Finance

 

 

 

 

 

 

 

Leases

 

 

Leases

 

2021

 

$

42,284

 

$

1,384

 

2022

 

 

72,260

 

 

1,930

 

2023

 

 

49,569

 

 

963

 

2024

 

 

35,148

 

 

393

 

2025

 

 

30,519

 

 

337

 

Thereafter

 

 

118,761

 

 

895

 

Total future lease payments

 

 

348,541

 

 

5,902

 

Less: imputed interest

 

 

(30,301)

 

 

(201)

 

Total

 

$

318,240

 

$

5,701

 

(unaudited
)
16
Supplemental cash flow information related to leases is as follows:
Three Months Ended
March 27,
March 28,
2021
2020
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows for operating leases
$
19,150
$
19,146
Operating cash flows for finance leases
23
27
Financing cash flows for finance leases
625
495
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
$
32,388
$
8,065
Finance leases
99
1,222
Maturities of lease liabilities are as follows:
March 27, 2021
Operating
Finance
Leases
Leases
2021
$
57,860
$
1,821
2022
64,241
1,545
2023
46,827
643
2024
32,991
329
2025
29,515
294
Thereafter
117,566
883
Total future
lease payments
349,000
5,515
Less: imputed interest
(31,796)
(202)
Total
$
317,204
$
5,313

As of March 27,June 26, 2021, we have additional operating leases with total lease payments

of $
11.1
$12.5 million for
buildings
and vehicles
that have not yet commenced.
These operating leases will commence subsequent to March
27,June 26, 2021,
with lease terms of
two years to 10 years.

17


to
10 years
.

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
17

Note 7 – Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right, at

certain times, to require us to acquire
their ownership interest in those entities at fair value.
Accounting Standards Codification (“ASC”) Topic 480-10 is
applicable for noncontrolling interests where we are or may be required
to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling
interest holder under the terms of a put
option contained in contractual agreements.
The components of the change in the redeemable noncontrolling
interests for the threesix months ended March 27,June 26, 2021 and the year ended December
26, 2020 are presented in the
following table:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Balance, beginning of period

 

$

327,699

 

$

287,258

Decrease in redeemable noncontrolling interests due to

 

 

 

 

 

 

 

redemptions

 

 

(1,130)

 

 

(17,241)

Increase in redeemable noncontrolling interests due to business

 

 

 

 

 

 

 

acquisitions

 

 

140,155

 

 

28,387

Net income attributable to redeemable noncontrolling interests

 

 

14,033

 

 

13,363

Dividends declared

 

 

(9,954)

 

 

(12,631)

Effect of foreign currency translation gain (loss) attributable to

 

 

 

 

 

 

 

redeemable noncontrolling interests

 

 

570

 

 

(4,279)

Change in fair value of redeemable securities

 

 

132,708

 

 

32,842

Balance, end of period

 

$

604,081

 

$

327,699

March 27,
December 26,
2021
2020
Balance, beginning of period
$
327,699
$
287,258
Decrease in redeemable noncontrolling interests due to
redemptions
0
(17,241)
Increase in redeemable noncontrolling interests due to business
acquisitions
85,037
28,387
Net income attributable to redeemable noncontrolling interests
7,053
13,363
Dividends declared
(6,237)
(12,631)
Effect of foreign currency translation loss attributable to
redeemable noncontrolling interests
(6,173)
(4,279)
Change in fair value of redeemable securities
45,520
32,842
Balance, end of period
$
452,899
$
327,699

Note 8 – Comprehensive Income

Comprehensive income includes certain gains and losses that, under U.S.

GAAP,
are excluded from net income as
such amounts are recorded directly as an adjustment to stockholders’
equity.

The following table summarizes our Accumulated other comprehensive loss, net of

applicable taxes as of:

 

 

 

 

June 26,

 

December 26,

 

 

 

 

2021

 

2020

Attributable to Redeemable noncontrolling interests:

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

$

(24,047)

 

$

(24,617)

 

 

 

 

 

 

 

 

 

Attributable to noncontrolling interests:

 

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

$

466

 

$

235

 

 

 

 

 

 

 

 

 

Attributable to Henry Schein, Inc.:

 

 

 

 

 

 

 

Foreign currency translation adjustment

 

$

(77,709)

 

$

(76,565)

 

Unrealized loss from foreign currency hedging activities

 

 

(9,878)

 

 

(11,488)

 

Unrealized investment gain (loss)

 

 

(2)

 

 

1

 

Pension adjustment loss

 

 

(19,190)

 

 

(20,032)

 

 

Accumulated other comprehensive loss

 

$

(106,779)

 

$

(108,084)

 

 

 

 

 

 

 

 

 

Total Accumulated other comprehensive loss

 

$

(130,360)

 

$

(132,466)

18


March 27,
December 26,
2021
2020
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment
$
(30,790)
$
(24,617)
Attributable to noncontrolling interests:
Foreign currency translation adjustment
$
310
$
235
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment
$
(108,948)
$
(76,565)
Unrealized loss from foreign currency hedging activities
(8,127)
(11,488)
Unrealized investment gain (loss)
(5)
1
Pension adjustment loss
(19,225)
(20,032)
Accumulated other comprehensive loss
$
(136,305)
$
(108,084)
Total Accumulated
other comprehensive loss
$
(166,785)
$
(132,466)

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
18

The following table summarizes the components of comprehensive income, net

of applicable taxes as follows:

 

 

Three Months Ended

 

Six Months Ended

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

2021

 

2020

 

2021

 

2020

Net income (loss)

 

$

163,977

 

$

(13,267)

 

$

338,905

 

$

120,298

 

 

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation gain (loss)

 

 

38,138

 

 

34,408

 

 

(343)

 

 

(54,904)

Tax effect

 

 

0

 

 

0

 

 

0

 

 

0

Foreign currency translation gain (loss)

 

 

38,138

 

 

34,408

 

 

(343)

 

 

(54,904)

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain (loss) from foreign currency hedging

 

 

 

 

 

 

 

 

 

 

 

 

activities

 

 

(2,438)

 

 

(6,733)

 

 

2,257

 

 

13,500

Tax effect

 

 

687

 

 

1,744

 

 

(647)

 

 

(3,346)

Unrealized gain (loss) from foreign currency hedging

 

 

 

 

 

 

 

 

 

 

 

 

activities

 

 

(1,751)

 

 

(4,989)

 

 

1,610

 

 

10,154

 

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized investment gain (loss)

 

 

4

 

 

3

 

 

(4)

 

 

(8)

Tax effect

 

 

(1)

 

 

(1)

 

 

1

 

 

1

Unrealized investment gain (loss)

 

 

3

 

 

2

 

 

(3)

 

 

(7)

 

 

 

 

 

 

 

 

 

 

 

 

 

Pension adjustment gain (loss)

 

 

(3)

 

 

(350)

 

 

1,023

 

 

698

Tax effect

 

 

38

 

 

125

 

 

(181)

 

 

(199)

Pension adjustment gain (loss)

 

 

35

 

 

(225)

 

 

842

 

 

499

Comprehensive income

 

$

200,402

 

$

15,929

 

$

341,011

 

$

76,040

Three Months Ended
March 27,
March 28,
2021
2020
Net income
$
174,928
$
133,565
Foreign currency translation loss
(38,481)
(89,312)
Tax effect
0
0
Foreign currency translation loss
(38,481)
(89,312)
Unrealized

The change in the unrealized gain (loss) from foreign currency hedging activities

4,695
20,233
Tax effect
(1,334)
(5,090)
Unrealized gain from foreign currency hedging activities
3,361
15,143
Unrealized during the three months and year ended June 26, 2021, compared to the comparable prior year period, was primarily attributable to a net investment loss
(8)
(11)
Tax effect
2
2
Unrealized investment loss
(6)
(9)
Pension adjustment gain
1,026
1,048
Tax effect
(219)
(324)
Pension adjustment gain
807
724
Comprehensive income
$
140,609
$
60,111
hedge that was entered into during 2019. See Note 14-Derivatives and Hedging Activities

for further information.

Our financial statements are denominated in the U.S. Dollar currency.

Fluctuations in the value of foreign
currencies as compared to the U.S. Dollar may have a significant impact
on our comprehensive income.
The
foreign currency translation lossgain (loss) during the threesix months ended March
27,June 26, 2021 and threesix months ended March 28,
June 27, 2020 was primarily impacted by changes in foreign currency exchange rates
of the Euro, British Pound, Brazilian
Real, Australian Dollar and Canadian Dollar.

The following table summarizes our total comprehensive income, net of

applicable taxes, as follows:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

2021

 

2020

 

2021

 

2020

Comprehensive income attributable to

 

 

 

 

 

 

 

 

 

 

 

 

 

Henry Schein, Inc.

 

$

185,242

 

$

17,600

 

$

323,018

 

$

87,586

Comprehensive income (loss) attributable to

 

 

 

 

 

 

 

 

 

 

 

 

 

noncontrolling interests

 

 

1,437

 

 

(744)

 

 

3,390

 

 

(431)

Comprehensive income (loss) attributable to

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

 

13,723

 

 

(927)

 

 

14,603

 

 

(11,115)

Comprehensive income

 

$

200,402

 

$

15,929

 

$

341,011

 

$

76,040

19


Three Months Ended
March 27,
March 28,
2021
2020
Comprehensive income attributable to
Henry Schein, Inc.
$
137,776
$
69,986
Comprehensive income attributable to
noncontrolling interests
1,953
313
Comprehensive income (loss) attributable to
Redeemable noncontrolling interests
880
(10,188)
Comprehensive income
$
140,609
$
60,111

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
19

Note 9 – Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or

paid to transfer a liability in an orderly
transaction between market participants at the measurement date.
Fair value hierarchy distinguishes between
(1) market participant assumptions developed based on market data obtained
from independent sources (observable
inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best
information available in the circumstances (unobservable inputs).

The fair value hierarchy consists of three broad levels, which gives the

highest priority to unadjusted quoted prices
in active markets for identical assets or liabilities (Level 1) and the lowest priority
to unobservable inputs (Level 3).
The three levels of the fair value hierarchy are described as follows:

Level 1— Unadjusted quoted prices in active markets for identical assets
or liabilities that are accessible at the
measurement date.

Level 2— Inputs other than quoted prices included within Level 1 that are observable
for the asset or liability,
either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets;
quoted prices for identical or similar assets or liabilities in markets that are
not active; inputs other than quoted
prices that are observable for the asset or liability; and inputs that are
derived principally from or corroborated by
observable market data by correlation or other means.

Level 3— Inputs that are unobservable for the asset or liability.

The following section describes the fair values of our financial instruments

and the methodologies that we used to
measure their fair values.

Investments and notes receivable

There are no quoted market prices available for investments in unconsolidated

affiliates and notes receivable;
however, we believe the carrying amounts are a reasonable estimate of fair value based on the interest
rates in the
applicable markets.

Debt

The fair value of our debt (including bank credit lines) is classified as

Level 3 within the fair value hierarchy as of
March 27, June 26, 2021 and December 26, 2020 was estimated at $
685.1
$788.4 million and $
699.0
$699.0 million, respectively.
Factors
that we considered when estimating the fair value of our debt include
market conditions, such as interest rates and
credit spreads.

Derivative contracts

Derivative contracts are valued using quoted market prices and

significant other observable and unobservable
inputs.
We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange
rates.
Our derivative instruments primarily include foreign currency forward
agreements related to certain
intercompany loans, certain forecasted inventory purchase commitments with
foreign suppliers, foreign currency
forward contracts to hedge a portion of our euro-denominated foreign operations
which are designated as net
investment hedges and a total return swap for the purpose of economically
hedging our unfunded non-qualified
supplemental retirement plan and our deferred compensation plan.

20


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
20

The fair values for the majority of our foreign currency derivative contracts are

obtained by comparing our contract
rate to a published forward price of the underlying market rates, which
is based on market rates for comparable
transactions and are classified within Level 2 of the fair value hierarchy.
See

for further information.

Redeemable noncontrolling interests

The values for Redeemable noncontrolling interests are classified within

Level 3 of the fair value hierarchy and are
based on recent transactions and/or implied multiples of earnings.
See

for additional information.

The following table presents our assets and liabilities that are measured and

recognized at fair value on a recurring
basis classified under the appropriate level of the fair value hierarchy as of
March 27, June 26, 2021 and December 26, 2020:

 

 

 

 

June 26, 2021

 

 

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative contracts

 

$

0

 

$

1,471

 

$

0

 

$

1,471

 

Total return swaps

 

 

0

 

 

1,317

 

 

0

 

 

1,317

 

 

Total assets

 

$

0

 

$

2,788

 

$

0

 

$

2,788

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative contracts

 

$

0

 

$

9,542

 

$

0

 

$

9,542

 

 

Total liabilities

 

$

0

 

$

9,542

 

$

0

 

$

9,542

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

$

0

 

$

0

 

$

604,081

 

$

604,081

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 26, 2020

 

 

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative contracts

 

$

0

 

$

1,868

 

$

0

 

$

1,868

 

Total return swaps

 

 

0

 

 

1,565

 

 

0

 

 

1,565

 

 

Total assets

 

$

0

 

$

3,433

 

$

0

 

$

3,433

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Derivative contracts

 

$

0

 

$

11,765

 

$

0

 

$

11,765

 

 

Total liabilities

 

$

0

 

$

11,765

 

$

0

 

$

11,765

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Redeemable noncontrolling interests

 

$

0

 

$

0

 

$

327,699

 

$

327,699

2020:

21


March 27, 2021
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts
$
0
$
1,856
$
0
$
1,856
Total return
swaps
0
1,458
0
1,458
Total assets
$
0
$
3,314
$
0
$
3,314
Liabilities:
Derivative contracts
$
0
$
5,353
$
0
$
5,353
Total liabilities
$
0
$
5,353
$
0
$
5,353
Redeemable noncontrolling interests
$
0
$
0
$
452,899
$
452,899
December 26, 2020
Level 1
Level 2
Level 3
Total
Assets:
Derivative contracts
$
0
$
1,868
$
0
$
1,868
Total return
swaps
0
1,565
0
1,565
Total assets
$
0
$
3,433
$
0
$
3,433
Liabilities:
Derivative contracts
$
0
$
11,765
$
0
$
11,765
Total liabilities
$
0
$
11,765
$
0
$
11,765
Redeemable noncontrolling interests
$
0
$
0
$
327,699
$
327,699

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
21

Note 10

Business Acquisitions

Acquisitions

We completed acquisitions during the threesix months ended March 27,June 26, 2021 which were immaterial to our financial

statements.
The acquisitions that we completed included companies within
our Health care distribution and
Technology and value-added services segments.
Our The initial ownership interest we acquired ranges between
in these companies ranged from approximately
65
% 51% to
100
% 100%.
Acquisitions within our Health care distribution segment includeincluded companies that
specialize in the distribution of dental products, a provider of home medical supplies, and a provider of product kitting and sterile
packaging.
Within our Technology and value-added services segment, we acquired companies that focus on dental
marketing and website solutions, practice transition services, and business
analytics and intelligence software.

The following table summarizes the estimated fair value, as of the date

of acquisition, of consideration paid and net
assets acquired for acquisitions during the threesix months ended March 27,June 26, 2021.
While we use our best estimates
and assumptions to accurately value those assets acquired and liabilities
assumed at the acquisition date as well as
contingent consideration, where applicable, our estimates are inherently uncertain
and subject to refinement.
As a
result, during the measurement period we may record adjustments to
the assets acquired and liabilities assumed
with the corresponding offset to goodwill within our consolidated balance sheets.

Acquisition consideration:

 

 

Cash

$

310,523

Redeemable noncontrolling interests

 

129,319

Total consideration

 

439,842

 

 

 

Identifiable assets acquired and liabilities assumed:

 

 

Current assets

 

107,197

Intangible assets

 

183,796

Other noncurrent assets

 

33,959

Current liabilities

 

(43,781)

Deferred income taxes

 

(17,442)

Other noncurrent liabilities

 

(37,462)

Total identifiable net assets

 

226,267

Goodwill

 

213,575

Total net assets acquired

$

439,842

Acquisition consideration:
Cash
$
213.8
Redeemable noncontrolling interests
75.2
Total consideration
289.0
Identifiable assets acquired and liabilities assumed:
Current assets
86.9
Intangible assets
151.4
Other noncurrent assets
19.0
Current liabilities
(31.8)
Deferred income taxes
(9.4)
Other noncurrent liabilities
(22.4)
Total identifiable
net assets
193.7
Goodwill
95.3
Total net assets acquired
$
289.0

The major classes of assets and liabilities that we generally allocate purchase

price to, excluding goodwill, include
identifiable intangible assets (i.e., trademarks and trade names, customer
relationships and lists, non-compete
agreements and product development), property, plant and equipment, deferred taxes and other current and long-
termlong-term assets and liabilities.
The estimated fair value of identifiable intangible assets is based on critical
estimates,
judgments and assumptions derived from analysis of market conditions,
discount rates, discounted cash flows,
customer retention rates and estimated useful lives.

Some prior owners of acquired subsidiaries are eligible to receive additional

purchase price cash consideration if
certain financial targets are met.
We have accrued liabilities for the estimated fair value of additional purchase
price consideration at the time of the acquisition.
Any adjustments to these accrual amounts are recorded in our
consolidated statements of income.
For the threesix months ended March 27,June 26, 2021 and March 28,June 27, 2020,
there were no
material adjustments recorded in our consolidated statements of income
relating to changes in estimated contingent
purchase price liabilities.

22


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
22

Note 11 – Plans of Restructuring

On November 20, 2019, we committed to a contemplated initiative, intended

to mitigate stranded costs associated
with the Animal Health Spin-off and to rationalize operations and to provide expense
efficiencies.
These activities
were originally expected to be completed by the end of 2020.
In light of the changes to the business environment
brought on by the COVID-19 pandemic, we extended such activities
to the end of 2021.

During the three months ended March 27,June 26, 2021 and March 28,June 27, 2020, we

recorded restructuring costs of $
2.9
$0.6 million and $
4.8
$15.9 million. During the six months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $3.5 million respectively.and $20.7 million. The restructuring costs for these periods included costs for severance
benefits and facility exit costs.
The costs associated with these restructurings are included in
a separate line item,
“Restructuring “Restructuring costs” within our consolidated statements of income.

We are currently unable in good faith to make a determination of an estimate of the amount or range of

amounts expected to be incurred in connection with these activities
in 2021, both with respect to each major type of
cost associated therewith and with respect to the total cost, or an estimate
of the amount or range of amounts that
will result in future cash expenditures.

The following table shows the net amounts expensed and paid for restructuring

costs that were incurred during the
three six months ended March 27,June 26, 2021 and during our 2020 fiscal year
and the remaining accrued balance of
restructuring costs as of March 27,June 26, 2021, which is included in Accrued
expenses: Other within our consolidated
balance sheets:

 

 

 

 

 

 

Facility

 

 

 

 

 

 

 

 

 

Severance

 

Closing

 

 

 

 

 

 

 

 

 

Costs

 

Costs

 

Other

 

Total

Balance, December 28, 2019

 

$

12,911

 

$

826

 

$

73

 

$

13,810

Provision

 

 

25,855

 

 

5,878

 

 

360

 

 

32,093

Payments and other adjustments

 

 

(26,152)

 

 

(6,309)

 

 

(329)

 

 

(32,790)

Balance, December 26, 2020

 

$

12,614

 

$

395

 

$

104

 

$

13,113

Provision

 

 

3,436

 

 

(122)

 

 

221

 

 

3,535

Payments and other adjustments

 

 

(12,736)

 

 

50

 

 

(321)

 

 

(13,007)

Balance, June 26, 2021

 

$

3,314

 

$

323

 

$

4

 

$

3,641

Facility
Severance
Closing
Costs
Costs
Other
Total
Balance, December 28, 2019
$
12,911
$
826
$
73
$
13,810
Provision
25,855
5,878
360
32,093
Payments and other adjustments
(26,152)
(6,309)
(329)
(32,790)
Balance, December 26, 2020
$
12,614
$
395
$
104
$
13,113
Provision
2,848
(151)
234
2,931
Payments and other adjustments
(8,623)
156
(243)
(8,710)
Balance, March 27, 2021
$
6,839
$
400
$
95
$
7,334

The following table shows, by reportable segment, the net amounts

expensed and paid for restructuring costs that
were incurred during the threesix months ended March 27,June 26, 2021 and during
our 2020 fiscal year and the remaining
accrued balance of restructuring costs as of March 27,June 26, 2021:

 

 

 

 

 

 

Technology and

 

 

 

 

 

Health Care

 

Value-Added

 

 

 

 

 

 

Distribution

 

Services

 

Total

Balance, December 28, 2019

 

$

13,373

 

$

437

 

$

13,810

Provision

 

 

30,935

 

 

1,158

 

 

32,093

Payments and other adjustments

 

 

(31,484)

 

 

(1,306)

 

 

(32,790)

Balance, December 26, 2020

 

$

12,824

 

$

289

 

$

13,113

Provision

 

 

3,082

 

 

453

 

 

3,535

Payments and other adjustments

 

 

(12,561)

 

 

(446)

 

 

(13,007)

Balance, June 26, 2021

 

$

3,345

 

$

296

 

$

3,641

23


Technology
and
Health Care
Value-Added
Distribution
Services
Total
Balance, December 28, 2019
$
13,373
$
437
$
13,810
Provision
30,935
1,158
32,093
Payments and other adjustments
(31,484)
(1,306)
(32,790)
Balance, December 26, 2020
$
12,824
$
289
$
13,113
Provision
2,803
128
2,931
Payments and other adjustments
(8,531)
(179)
(8,710)
Balance, March 27, 2021
$
7,096
$
238
$
7,334

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
23

Note 12

Earnings Per Share

Basic earnings per share is computed by dividing net income attributable

to Henry Schein, Inc. by the weighted-
averageweighted-average number of common shares outstanding for the period.
Our diluted earnings per share is computed similarly
to basic earnings per share, except that it reflects the effect of common shares issuable
for presently unvested
restricted stock and restricted stock units and upon exercise of stock options
using the treasury stock method in
periods in which they have a dilutive effect.

A reconciliation of shares used in calculating earnings per basic and

diluted share follows:

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

2021

 

2020

 

2021

 

2020

Basic

 

140,358

 

142,350

 

141,316

 

142,654

Effect of dilutive securities:

 

 

 

 

 

 

 

 

 

Stock options, restricted stock and restricted stock units

 

1,299

 

0

 

1,222

 

0

 

Diluted

 

141,657

 

142,350

 

142,538

 

142,654

24


Three Months Ended
March 27,
March 28,
2021
2020
Basic
142,298
142,967
Effect of dilutive securities:
Stock options, restricted stock and restricted stock units
1,100
128
Diluted
143,398
143,095

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
24

Note 13 – Income Taxes

For the threesix months ended March 27,June 26, 2021 our effective tax rate was

25.1
% 24.3% compared to
22.4
% 24.2% for the prior year
period.
The difference between our effective tax rates and the federal statutory tax rate for the six months ended June 26, 2021 primarily relates to state and foreign income taxes, interest expense and tax charges and credits associated with legal entity reorganizations. The difference between our effective tax rate and the federal statutory tax rate for the
three
six months ended
MarchJune 27, 2021 was2020 primarily due to state and foreign income taxes and interest
expense.
The difference between
our effective tax rate and the federal statutory tax rate for the three months ended
March 28, 2020 primarily relates
to state and foreign income taxes and interest expense, as well as tax charges and credits associated
with legal entity
reorganizations outside the United States.
U.S and a valuation allowance recognized on a portion of a deferred tax asset.

The American Rescue Plan Act of 2021 (“ARPA”) was signed into law on March 11, 2021.

The ARPA included a
corporate income tax provision to further limit the deductibility of compensation
under Section 162(m) for tax
years starting after December 31, 2026.
Section 162(m) generally limits the deductibility of compensation paid
to
covered employees of publicly held corporations.
Covered employees include the CEO, CFO and the three highest
paid officers. The ARPA expands the group of covered employees to additionally include five of the highest paid
employees.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act

(“ (“CARES Act”) was enacted in
response to the COVID-19 pandemic.
The CARES Act includes, but is not limited to, certain income tax
provisions that modify the Section 163(j) limitation of business interest and
net operating loss carryover and
carryback rules.
We have analyzed the income tax provisions of the CARES Act and have accounted for the
impact in the threesix months ended March 28,June 27, 2020, which did not have a
material impact on our consolidated
financial statements.
There are certain other non-income tax benefits available to us under
the CARES Act that
require further clarification or interpretation that may affect our consolidated financial statements
in the future.

The total amount of unrecognized tax benefits, which are included in “Other

liabilities” within our consolidated
balance sheets, as of March 27,June 26, 2021 was approximately $
89.2
$79.3 million, of which $
73.0
$63.9 million would affect the
effective tax rate if recognized.
It is possible that the amount of unrecognized tax benefits will
change in the next
12 months, which may result in a material impact on our consolidated statements
of income.

The tax years subject to examination by major tax jurisdictions include years 2012, 2013, 2017 and forward by the

U.S Internal Revenue Service (the “IRS”) as well as the years 2008 and forward for certain states and certain
foreign jurisdictions. All tax returns audited by the IRS are officially closed through 2011 and 2014 through
2016. We are currently under auditDuring the quarter ended June 26, 2021 we reached a resolution with the IRSAppellate Division for the yearsall remaining outstanding issues for 2012 and 2013 and all fieldwork has been completed.
2013. The resolution did not have a material impact to our consolidated financial statements. We reached a settlement with the U.S. Competent Authority to resolve certain transfer pricing issues related to
2012 and 2013 in the quarter ended December 28, 2019. For all remaining outstanding issues for 2012 and 2013,
we have provided all necessary documentation toDuring the Appellate Division to date and are waiting for responses. We
do not believe the final resolution will have a material impact to our consolidated financial statements. During the
quarter ended September 26, 2020 we finalized negotiations with the Advance Pricing Division and reached an
agreement on an appropriate transfer pricing methodology for the years 2014-2025. The objective of this resolution
was to mitigate future transfer pricing audit adjustments. In the fourth quarter of 2020, we reached a favorable
resolution with the IRS relating to select audit years.

The total amounts of interest and penalties are classified as a component of

the provision for income taxes. The
amount of tax interest expenseexpense/(credit) was approximately $
0.5
$(2.7) million for the threesix months ended March 27,June 26, 2021, and
$
0.3
$1.8 million for the threesix months ended March 28,June 27, 2020.
The total amount of accrued interest is included in “Other
liabilities”, liabilities,” and was approximately $
14.6
$11.3 million as of March 27,June 26, 2021 and $
14.0
$14.0 million as of December 26, 2020.
NaN
penalties were accrued for the periods presented.

25


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
25

Note 14

Derivatives and Hedging Activities

We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S.

dollar and each other, and changes to the credit risk of the derivative counterparties.
We attempt to minimize these
risks by primarily using foreign currency forward contracts and by
maintaining counter-party credit limits.
These
hedging activities provide only limited protection against currency exchange
and credit risks.
Factors that could
influence the effectiveness of our hedging programs include currency markets and
availability of hedging
instruments and liquidity of the credit markets.
All foreign currency forward contracts that we enter into are
components of hedging programs and are entered into for the sole purpose
of hedging an existing or anticipated
currency exposure.
We do not enter into such contracts for speculative purposes and we manage our credit risks by
diversifying our counterparties, maintaining a strong balance sheet and having
multiple sources of capital.

During 2019

we entered into foreign currency forward contracts to hedge a portion of our euro-denominated
foreign operations which are designated as net investment hedges. These net investment hedges offset the change
in the U.S dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign
exchange rates.
Gains and losses related to these net investment hedges are recorded
in
Accumulated other
comprehensive loss
within our consolidated balance sheets.
Amounts excluded from the assessment of hedge
effectiveness are included in interest expense within our consolidated statements
of income.
The aggregate
notional value of this net investment hedge, which matures on
November 16, 2023,
, is approximately
200
€200 million.
During the three months ended March 27,June 26, 2021 and March 28,June 27, 2020,
we recognized approximately $
1.1
$1.1 million and $
1.2
$1.2 million, respectively, of interest savings as a result of this net investment hedge.
During the six months ended June 26, 2021 and June 27, 2020, we recognized approximately $2.2 and $2.4 million, respectively, of interest savings as a result of this net investment hedge.

On

March 20, 2020,
,
we entered into a total return swap for the purpose of economically hedging our unfunded non-
qualifiednon-qualified supplemental retirement plan (“SERP”) and our deferred compensation plan (“DCP”). This swap will
offset changes in our SERP and DCP liabilities.
At the inception, the notional value of the investments in these
plans was $
43.4
$43.4 million.
At March 27,June 26, 2021, the notional value of the investments in
these plans was $
77.5
$84.8 million.
At March 27,June 26, 2021, the financing blended rate for this swap was
based on LIBOR of
0.12
% 0.09% plus
0.50
% 0.47%,
for a combined rate of
0.62
% 0.56%.
For the three months and six months ended March 27,June 26, 2021, we have recorded a
gain, within the
selling, general and administrative line item in our consolidated statement
of income, of approximately $
2.7
$5.4 million and $8.1 million, respectively, net of transaction costs, related to this undesignated swap.
For the three months and six months ended June 27, 2020, we have recorded a gain, within the selling, general and administrative line item in our consolidated statement of income, of approximately $6.7 million and $10.3 million, respectively, net of transaction costs, related to this undesignated swap. This swap is expected to be renewed on an
annual basis after its current expiration date of March 29, 2022, and
is expected to result in a neutral impact to our
results of operations.

Fluctuations in the value of certain foreign currencies as compared

to the U.S. dollar may positively or negatively
affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed
in U.S.
dollars.
Where we deem it prudent, we engage in hedging programs using primarily
foreign currency forward
contracts aimed at limiting the impact of foreign currency exchange
rate fluctuations on earnings.
We purchase
short-term (i.e., generally
18
months or less) foreign currency forward contracts to protect against
currency
exchange risks associated with intercompany loans due from our international
subsidiaries and the payment of
merchandise purchases to our foreign suppliers.
We do not hedge the translation of foreign currency profits into
U.S. dollars, as we regard this as an accounting exposure, not an
economic exposure.
Our hedging activities have
historically not had a material impact on our consolidated financial statements.
Accordingly, additional disclosures
related to derivatives and hedging activities required by ASC 815 have
been omitted.

26


HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED

FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

(unaudited
)
26

Note 15 – Stock-Based Compensation

Our accompanying consolidated statements of income reflect pre-tax share-based

compensation expense of $
12.8
$17.4 million ($
9.6
13.3 million after-tax) and $30.2 million ($22.8 million after-tax) for the three and six months ended MarchJune 26, 2021, respectively. For the three and six months ended June 27, 20212020 we recorded pre-tax share-based compensation expense of $5.2 million ($4.2 million after-tax) and pre-tax share
based compensation
a credit of $
17.5
$12.4 million ($
13.6
9.4 million after-tax) for the three months ended March 28, 2020.
, respectively. The $
17.5
$12.4 million
credit for share-based compensation during the threesix months ended March
28,June 27, 2020 reflected our reduced estimate
in expected achievement of performanceperformance-based targets resulting from the impact of COVID-19.

Our accompanying consolidated statements of cash flows present our

stock-based compensation expense (credit) as
an adjustment to reconcile net income to net cash provided by operating activities
for all periods presented.
In the
accompanying consolidated statements of cash flows, there were
0
benefits associated with tax deductions in
excess of recognized compensation as a cash inflow from financing
activities for the threesix months ended March 27,
June 26, 2021 and March 28,June 27, 2020, respectively.

Stock-based compensation represents the cost related to stock-based awards granted

to employees and non-
employeenon-employee directors.
We measure stock-based compensation at the grant date, based on the estimated fair value of
the award, and recognize the cost (net of estimated forfeitures) as compensation
expense over the requisite service
period.
Our stock-based compensation expense is reflected in selling, general
and administrative expenses in our
consolidated statements of income.

Stock-based awards are provided to certain employees and non-employee directors

under the terms of our 2020
Stock Incentive Plan and our 2015 Non-Employee Director Stock Incentive Plan
(together, (together, the “Plans”).
The Plans
are administered by the Compensation Committee of the Board of Directors
(the (the “Compensation
Committee”).
Historically, equity-based awards have been granted solely in the form of restricted stock units
(“RSUs”).
However, beginning in March 2021, our equity-based awards werehave been granted in the form of RSUs and non-qualified
stock options.

Grants of RSUs are stock-based awards granted to recipients with specified

vesting provisions.
In the case of
RSUs, common stock is generally delivered on or following satisfaction of vesting
conditions.
We issue RSUs that
vest solely based on the recipient’s continued service over time (primarily four-year cliff vesting, except for grants
made under the 2015 Non-Employee Director Stock Incentive Plan, which
are primarily
12
-month 12-month cliff vesting),
and RSUs that vest based on our achieving specified performance measurements
and the recipient’s continued
service over time (primarily three-year cliff vesting).
For these RSUs, we recognize the cost as compensation
expense on a straight-line basis.

During the three months ended March 27, 2021, as a result of the continuing

economic risk and uncertainty
resulting from the ongoing COVID-19 pandemic, the Compensation Committee
decided to adjust the form of
awards granted under our 2021 long-term incentive program for our 2021
fiscal year in a manner that focuses on
our long-term value by granting stock options and time-based RSUs rather
than performance-based RSUs.
Stock
options are awards that allow the recipient to purchase shares of our common
stock at a fixed price following
vesting of the stock options.
Stock options are granted at an exercise price equal to our closing stock
price on the
date of grant.
Stock options issued during 2021 vest
one-third
per year based on the recipient’s continued service,
subject to the terms and conditions of the Plans, are fully vested
three years
from the grant date and have a
contractual term of
ten years
from the grant date, subject to earlier termination of the term upon certain events.
Compensation expense for these stock options is recognized using a graded vesting
method.
We estimate the fair
value of stock options using the Black-Scholes valuation model.

27


Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

In addition to equity-based awards under the 2021 long-term incentive

program under the 2020 Stock Incentive
Plan, the Compensation Committee granted a Special Pandemic
Recognition Award under the 2020 Stock Incentive
Plan to recipients of performance-based RSUs under the 2018 long-term incentive
program.
These awards will vest
50
% 50% on the first anniversary of the grant date and
50
% 50% on the second anniversary of the grant date and are recorded
as compensation expense using a graded vesting method.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited
)
27

With respect to time-based RSUs, we estimate the fair value on the date of grant based on our closing

stock price at
time of grant.
With respect to performance-based RSUs, the number of shares that ultimately vest and are received
by the recipient is based upon our performance as measured against specified
targets over a specified period, as
determined by the Compensation Committee.
Although there is no guarantee that performance targets will be
achieved, we estimate the fair value of performance-based RSUs based on
our closing stock price at time of grant.

The Plans provide for adjustments to the performance-based restricted

stock units targets for significant events,
including, without limitation, acquisitions, divestitures, new business ventures,
certain capital transactions
(including (including share repurchases), restructuring costs, if any, certain litigation settlements or payments, if any, changes
in accounting principles or in applicable laws or regulations, changes
in income tax rates in certain markets and
foreign exchange fluctuations.
Over the performance period, the number of shares of common
stock that will
ultimately vest and be issued and the related compensation expense
is adjusted upward or downward based upon
our estimation of achieving such performance targets.
The ultimate number of shares delivered to recipients and
the related compensation cost recognized as an expense will be based
on our actual performance metrics as defined
under the Plans.

Total unrecognized compensation cost related to unvested awards as of March 27,June 26, 2021 was $

110.0
$99.0 million, which
is expected to be recognized over a weighted-average period of approximately
2.8
2.5 years.

The following weighted-average assumptions were used in determining

the most recent fair values of stock options using the
Black-Scholes valuation model:

Expected dividend yield

0.0

%

Expected stock price volatility

26.60

%

Risk-free interest rate

0.94

%

Expected life of options (years)

6.00

Expected dividend yield
0.0
%
Expected stock price volatility
25.80
%
Risk-free interest rate
0.94
%
Expected life of options (years)
6.00

We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in

the foreseeable future. The expected stock price volatility is based
on implied volatilities from traded options on our
stock, historical volatility of our stock, and other factors. The
risk-free interest rate is based on the U.S. Treasury
yield curve in effect at the time of grant in conjunction with considering the expected
life of options. The
6
-year
6-year expected life of the options was determined using the simplified method
for estimating the expected term as
permitted under SAB Topic 14.
Estimates of fair value are not intended to predict actual future events or
the value
ultimately realized by recipients of stock options, and subsequent events
are not indicative of the reasonableness of
the original estimates of fair value made by us.

28


Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

The following table summarizes stock option activity under the Plans during

the threesix months ended March 27,
June 26, 2021:

 

 

 

 

 

 

 

Weighted

 

 

 

 

 

 

 

 

 

 

Average

 

 

 

 

 

 

 

Weighted

 

Remaining

 

 

 

 

 

 

 

Average

 

Contractual

 

Aggregate

 

 

 

 

Exercise

 

Life in

 

Intrinsic

 

 

Shares

 

Price

 

Years

 

Value

Outstanding at beginning of period

 

0

 

$

0

 

 

 

 

 

Granted

 

794

 

 

62.82

 

 

 

 

 

Exercised

 

0

 

 

0

 

 

 

 

 

Forfeited

 

(2)

 

 

62.71

 

 

 

 

 

Outstanding at end of period

 

792

 

$

62.82

 

9.7

 

$

12.21

 

 

 

 

 

 

 

 

 

 

 

Options exercisable at end of period

 

1

 

$

0

 

-

 

$

0

Weighted
Average
Weighted
Remaining
Average
Contractual
Aggregate
Exercise
Life in
Intrinsic
Shares
Price
Years
Value
Outstanding at beginning of period
0
$
0
Granted
788
62.71
Forfeited
0
0
Outstanding at end of period
788
$
62.71
9.9
$
4,152
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited
)
28

The following tables summarize the activity of our unvested RSUs for

the threesix months ended March 27,June 26, 2021:

 

 

Time-Based Restricted Stock Units

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

Grant Date Fair

 

 

Intrinsic Value

 

 

Shares/Units

 

Value Per Share

 

 

Per Share

Outstanding at beginning of period

 

1,459

 

$

57.61

 

 

 

 

Granted

 

821

 

 

63.02

 

 

 

 

Vested

 

(266)

 

 

66.85

 

 

 

 

Forfeited

 

(19)

 

 

60.47

 

 

 

 

Outstanding at end of period

 

1,995

 

$

58.64

 

 

$

75.01

 

 

 

 

 

 

 

 

 

 

 

 

Performance-Based Restricted Stock Units

 

 

 

 

Weighted Average

 

 

 

 

 

 

 

Grant Date Fair

 

 

Intrinsic Value

 

 

Shares/Units

 

Value Per Share

 

 

Per Share

Outstanding at beginning of period

 

136

 

$

53.52

 

 

 

 

Granted

 

286

 

 

58.60

 

 

 

 

Vested

 

(83)

 

 

52.30

 

 

 

 

Forfeited

 

(9)

 

 

59.46

 

 

 

 

Outstanding at end of period

 

330

 

$

59.50

 

 

$

75.01

Time-Based Restricted Stock Units
Weighted Average
Grant Date Fair
Intrinsic Value
Shares/Units
Value Per Share
Per Share
Outstanding at beginning of period
1,459
$
57.61
Granted
797
62.75
Vested
(256)
66.92
Forfeited
(7)
59.59
Outstanding at end of period
1,993
$
58.46
$
67.98
Performance-Based Restricted Stock Units
Weighted Average
Grant Date Fair
Intrinsic Value
Shares/Units
Value Per Share
Per Share
Outstanding at beginning of period
136
$
53.52
Granted
189
58.35
Vested
(78)
51.92
Forfeited
(4)
59.05
Outstanding at end of period
243
$
59.21
$
67.98

Note 16 – Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

 

 

Six Months Ended

 

 

June 26,

 

June 27,

 

 

2021

 

2020

Interest

 

$

13,605

 

$

16,925

Income taxes

 

 

134,232

 

 

31,553

Three Months Ended
March 27,
March 28,
2021
2020
Interest
$
7,763
$
9,951
Income taxes
13,425
12,613

During the threesix months ended March 27,June 26, 2021 and March 28,June 27, 2020, we

had a $
4.7
$2.3 million and $
20.2
$13.5 million of
non-cash net unrealized gains related to foreign currency hedging activities, respectively.

29

respectively.

Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Note 17 – Legal Proceedings

On

August 31, 2012
,
Archer and White Sales, Inc.
(“Archer”) filed a complaint against
Henry Schein, Inc. as well
as Danaher Corporation and its subsidiaries Instrumentarium Dental, Inc., Dental Equipment, LLC, Kavo Dental
Technologies, LLC and Dental Imaging Technologies Corporation (collectively, the “Danaher Defendants”)
in the
U.S. District Court for the Eastern District of Texas, Civil Action No. 2:12-CV-00572-JRG, styled as an antitrust
action under Section 1 of the Sherman Act, and the Texas Free Enterprise Antitrust Act.
Archer allegesalleged a
conspiracy between Henry Schein, an unnamed company and the Danaher Defendants to terminate or limit
Archer’s distribution rights.
On
August 1, 2017
,
Archer
filed an amended complaint, adding
Patterson Companies,
Inc. (“Patterson”) and Benco Dental Supply Co. (“Benco”) as defendants,
, and
alleging that Henry Schein,
Patterson, Benco and Burkhart Dental Supply conspired to fix prices and refused to compete with each other for
sales of dental equipment to dental professionals and agreed to enlist their common suppliers, the Danaher
Defendants, to join a price-fixing conspiracy and boycott by reducing the distribution territory of, and eventually
terminating, their price-cutting competing distributor Archer.
Archer seekssought damages in an amount to be proved at
trial, to be
trebled with interest and costs, including attorneys’ fees, jointly and severally, as well as injunctive
relief.
On
October 30, 2017
,
Archer
filed a second amended complaint, to
add additional allegations that it believes
support its claims. The named parties and causes of action arewere the same as the August 1, 2017 amended complaint.
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited
)
29

On October 1, 2012, we filed a motion for an order: (i) compelling Archer

to arbitrate its claims against us; (2)
staying all proceedings pending arbitration; and (3) joining the Danaher
Defendants’ motion to arbitrate and stay.
On May 28, 2013, the Magistrate Judge granted the motions to arbitrate
and stayed proceedings pending arbitration.
On June 10, 2013, Archer moved for reconsideration before the District Court
judge.
On December 7, 2016, the
District Court Judge granted Archer’s motion for reconsideration and lifted the stay.
Defendants appealed the
District Court’s order.
On December 21, 2017, the U.S. Court of Appeals for the Fifth Circuit
affirmed the District
Court’s order denying the motions to compel arbitration.
On June 25, 2018, the Supreme Court of the United States
granted defendants’ petition for writ of certiorari.
On October 29, 2018, the Supreme Court heard oral arguments.
On January 8, 2019, the Supreme Court issued its published decision vacating
the judgment of the Fifth Circuit and
remanding the case to the Fifth Circuit for further proceedings consistent with
the Supreme Court’s opinion.
On
April 2, 2019, the District Court stayed the proceeding in the trial court pending
resolution by the Fifth Circuit.
The
Fifth Circuit heard oral argument on May 1, 2019 on whether the case should be arbitrated.
The Fifth Circuit
issued its opinion on August 14, 2019 affirming the District Court’s order denying defendants’ motions to compel
arbitration.
Defendants filed a petition for rehearing en banc before the Fifth
Circuit.
The Fifth Circuit denied that
petition.
On October 1, 2019, the District Court set the case for trial
on February 3, 2020, which was subsequently
moved to January 29, 2020.
On January 24, 2020 the Supreme Court granted our motion to stay
the District Court
proceedings, pending the disposition of our petition for writ of certiorari, which
was filed on January 31, 2020.
Archer conditionally cross petitioned for certiorari on an arbitration issue
on March 2, 2020.
On June 15, 2020, the
Supreme Court granted our petition for writ of certiorari, and denied Archer’s conditional
petition for certiorari, and
thus the District Court proceedings remained stayed.
After briefing from the parties and several amici, the case was
argued before the Supreme Court on December 8, 2020.
On January 25, 2021, the Supreme Court dismissed the
writ of certiorari as improvidently granted.
That action dissolved the stay the Supreme Court had previously
granted.
The U.S. District Court for the Eastern District of Texas then set the case for trial, and jury selection was
scheduled to begin on June 1, 2021.
Patterson and the Danaher Defendants settled with Archer and
they have been
dismissed from the case with prejudice.
Benco has agreed to settle settled

30


Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

the case with the plaintiff. Henry Schein and the

plaintiff have agreed to settlesettled this matter for an amount that is not material to the Company
and to dismissCompany. The court dismissed the case
with prejudice.
prejudice on May 25, 2021.

On

May 29, 2018
, an amended complaint was filed in the MultiDistrict Litigation (“MDL”)
proceeding In Re
National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804)
in an action entitled
The County of
Summit, Ohio et al.
v. Purdue Pharma, L.P.,
et al., Civil Action No. 1:18-op-45090-DAP (“County of
Summit
Action”), in the U.S. District Court for the Northern District of Ohio,
adding Henry Schein, Inc., Henry Schein
Medical Systems, Inc. and others as defendants
.
defendants. Summit County alleged that manufacturers of prescription opioid
drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and
that the entities in the supply chain (including Henry Schein, Inc. and Henry Schein Medical Systems, Inc.) reaped
financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of
those drugs.
On October 29, 2019, the Company was dismissed with prejudice from this lawsuit. Henry Schein,
working with Summit County, donated $1$1 million to a foundation and paid $250,000 of Summit County’s
expenses, as described in our prior filings with the SEC.

In addition to the County of Summit Action,

Henry Schein and/or one or more of its affiliated companies
have been
named as a defendant in multiple lawsuits (currently less than one-hundred
and fifty (
150
)(150)), which
allege claims
similar to those alleged in the County of Summit Action
.Action. These actions consist of some that have been consolidated
within the MDL and are currently abated for discovery purposes, and others
which remain pending in state courts
and are proceeding independently and outside of the MDL.
On October 9, 2020, the Circuit Court of the 17th
Judicial Circuit in and for Broward County, Florida, Case No. CACE19018882, granted Henry Schein’s motion to
dismiss the claims brought against it in the action filed by North
Broward Hospital District et. al.
The Florida court
gave plaintiffs until November 24, 2020 to replead their claims against Henry Schein.
On January 8, 2021, Henry
Schein filed a motion to dismiss the Amended Complaint.
By Order entered on March 24, 2021, the Circuit Court
of Washington County,
Arkansas, Case No. 72-CV20-156, granted Henry Schein’s motion to dismiss the claims
brought against it in the action filed by Fayetteville Arkansas Hospital Company, LLC, et al.
The Arkansas court
gave plaintiffs until forty-five (45) days from the date the court entersfiled an order or orders deciding
all other motions
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited
)
30
to dismiss currently pending before the court, to replead their claims against
amended complaint on July 29, 2021and did not name Henry Schein.
Schein as a defendant. An action filed by
Tucson Medical Center et al. was previously scheduled for trial beginning on June
1, 2021 but the court has vacated
that trial date.
At this time, the only cases set for trial are the actions filed by
West Virginia
University Hospitals,
Inc. et al., which is currently scheduled for a non-jury liability trial on plaintiffs’ public
nuisance claims on
November 1, 2021, and DCH Health Care Authority, et al., which is currently scheduled for a liability jury trial on
plaintiffs’ public nuisance claims on July 18, 2022.
Of Henry Schein’s 2020 revenue of approximately $
10.1
$10.1 billion from continuing operations, sales of opioids represented less than
one-tenth of 1
percent.
Opioids represent
a negligible part of our business.
We intend to defend ourselves vigorously against these actions.

On

September 30, 2019
, the
City of Hollywood Police Officers Retirement System, individually and on behalf of
all others similarly situated,
, filed a putative class action complaint for violation of the federal
securities laws
against
Henry Schein, Inc., Covetrus, Inc., and Benjamin Shaw and Christine Komola (Covetrus’s then Chief
Executive Officer and Chief Financial Officer, respectively
)respectively) in the U.S. District Court for the Eastern District of
New York,
Case No. 2:19-cv-05530-FB-RLM.
The complaint seeks to certify a class consisting of all persons and
entities who, subject to certain exclusions, purchased or otherwise acquired Covetrus
common stock from February
8, 2019 through August 12, 2019.
The case relates to the Animal Health Spin-off and Merger of the Henry Schein
Animal Health Business with Vets First Choice in February 2019.
The complaint alleges violations of Sections
10(b) and 20(a) of the

31


Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

Securities Exchange Act of 1934, as amended, and Securities and Exchange Commission

Rule 10b-5 and asserts that defendants’ statements in the offering documents and after the transaction were
materially false and misleading
because they purportedly overstated Covetrus’s capabilities as to inventory
management and supply-chain services, understated the costs of integrating
the Henry Schein Animal Health
Business and Vets
First Choice, understated Covetrus’s separation costs from Henry Schein, and understated the
impact on earnings from online competition and alternative distribution
channels and from the loss of an allegedly
large customer in North America just before the Separation and Merger.
The complaint seeks unspecified monetary
damages and a jury trial.
Pursuant to the provisions of the PSLRA, the court appointed
lead plaintiff and lead
counsel on December 23, 2019.
Lead plaintiff filed a Consolidated Class Action Complaint on February 21,
2020.
Lead plaintiff added Steve Paladino, our Chief Financial Officer, as a defendant in the action.
Lead plaintiff filed
an Amended Consolidated Class Action Complaint on May 21, 2020,
in which it added a claim that Mr. Paladino is
a “control person” of Covetrus.
We intend to defend ourselves vigorously against this action.

On

February 5, 2021
,
Jack Garnsey filed a putative shareholder derivative action on behalf of Covetrus, Inc.
in the
U.S. District Court for the Eastern District of New York, naming as defendants
Benjamin Shaw, Christine T.
Komola, Steven Paladino, Betsy Atkins, Deborah G. Ellinger, Sandra L. Helton, Philip A. Laskaway, Mark J.
Manoff, Edward M. McNamara, Ravi Sachdev, David E. Shaw, Benjamin Wolin, and Henry Schein, Inc., with
Covetrus, Inc.
named as a nominal defendant.
The complaint alleges that
the individual defendants breached their
fiduciary duties under state law in connection with the same allegations asserted in the City of Hollywood securities
class action described above and further alleges that Henry Schein aided and abetted such breaches. The complaint
also asserts claims for contribution under the federal securities laws against Henry Schein and other defendants,
also arising out of the allegations in the City of Hollywood lawsuit.
The complaint seeks declaratory, injunctive,
and monetary relief. We intend to defend ourselves vigorously against this action.
On April 8, 2021 the Court
entered an order staying the Garnsey action until forty-five (
45
)(45) days after a decision is issued finally resolving the
motions to dismiss in the City of Hollywood Class Action.

From time to time, we may become a party to other legal proceedings,

including, without limitation, product
liability claims, employment matters, commercial disputes, governmental
inquiries and investigations (which may
in some cases involve our entering into settlement arrangements or consent
decrees), and other matters arising out
of the ordinary course of our business.
While the results of any legal proceeding cannot be predicted with certainty,
in our opinion none of these other pending matters are currently anticipated
to have a material adverse effect on our
consolidated financial position, liquidity or results of operations.

As of March 27,June 26, 2021, we had accrued our best estimate of potential losses relating to claims that were probable to

result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related
HENRY SCHEIN, INC.
NOTES TO CONSOLIDATED
FINANCIAL STATEMENTS
(in thousands, except per share data)
(unaudited
)
31
expenses, was not material to our financial position, results of operations or cash flows. Our method for
determining estimated losses considers currently available facts, presently enacted laws and regulations and other
factors, including probable recoveries from third parties.

Note 18 – Related Party Transactions

On February 7, 2019 (the “Distribution Date”), we completed the separation

(the (the “Separation”) and subsequent
merger (“Merger”) of our animal health business (the “Henry Schein Animal Health Business”) with Direct
Vet
Marketing, Inc. (d/b/a Vets First Choice, “Vets
First Choice”).
This was accomplished by a series of transactions
among us, Vets
First Choice, Covetrus, Inc. (f/k/a HS Spinco, Inc. “Covetrus”), a
wholly owned subsidiary of ours

32


Table of Contents

HENRY SCHEIN, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except per share data)

(unaudited)

prior to the Distribution Date, and HS Merger Sub, Inc., a wholly owned subsidiary

of Covetrus (“Merger Sub”).Covetrus. In
connection with the Separation, we contributed, assigned and transferred
to Covetrus certain applicable assets,
liabilities and capital stock or other ownership interests relating to the Henry
Schein Animal Health Business. On
the Distribution Date, we received a tax-free distribution of $
1,120
$1,120 million from Covetrus pursuant to certain debt
financing incurred by Covetrus. On the Distribution Date and prior to the
Animal Health Spin-off, Covetrus issued
shares of Covetrus common stock to certain institutional accredited investors
for $
361.1
$361.1 million (the “Share Sale”).
The proceeds of the Share Sale were paid to Covetrus and distributed to us. Subsequent
to the Share Sale, we
distributed, on a pro rata basis, all of the shares of the common stock
of Covetrus held by us to our stockholders of
record as of the close of business on January 17, 2019 (the “Animal Health
Spin-off”).

In connection with the completion of the Animal Health Spin-off during our 2019 fiscal year, we entered into a

transition services agreement with Covetrus under which we agreed to provide certain transition services for up to
twenty-four months in areas such as information technology, finance and accounting, human resources, supply
chain, and real estate and facility services.
Services provided under this transition services agreement ended in
December 2020.
During the three and six months ended March 28,June 27, 2020, we recorded approximately
$
4.4
$4.3 million and $8.8 million, respectively, of fees
for these services.
Covetrus also purchased certain products from us pursuant
to the transition services agreement,
which ended in December 2020.
During the three and six months ended March 28,June 27, 2020, net sales
to Covetrus were
approximately $
21.1
million.
$20.1 million and $41.2 million, respectively.

In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was

formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay
Internet Brands approximately $31.0$31.0 million annually for the use of their intellectual property.
During the three
and six months ended March 27,June 26, 2021, and March 28, 2020, we recorded $
7.8
million and $
7.8
$15.6 million, respectively in
connection with costs related to this royalty agreement.
During the three and six months ended June 27, 2020, we recorded $7.8 million and $15.6 million, respectively in connection with costs related to this royalty agreement. As of March 27,June 26, 2021 and December 26, 2020, Henry
Schein One, LLC had a net (payable) receivable balance due (to) from Internet Brands of
$
1.7
$(6.3) million and $
4.7
$4.7 million,
respectively, comprised of amounts related to results of operations and the royalty agreement.

During our normal course of business, we have interests in entities that we account for under the equity accounting

method.
During the three and six months ended MarchJune 26, 2021, we recorded net sales of $18.0 million and $33.4 million, respectively, to such entities. During the three and six months ended June 27, 2021 and March 28,
2020, we recorded net sales of $
15.5
$9.1 million and $
15.4
$24.5 million, respectively, to such entities.
During the three and six months ended March 27,June 26, 2021, and March
28, 2020, we purchased $
3.8
$5.3 million and $
3.0
$9.1 million, respectively, from such entities.
During the three and six months ended June 27, 2020, we purchased $1.7 million and $4.5 million, respectively, from such entities. At March 27,June 26, 2021 and
December 26, 2020, in the aggregate we had in aggregate $
36.7
$42.0 million and $
36.4
$36.4 million, due from our equity affiliates, and $
7.8
$10.1 million and $
8.6
$8.6 million due to our equity affiliates, respectively.

33


32

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS

Cautionary Note Regarding Forward-Looking Statements

In accordance with the “Safe Harbor” provisions of the Private Securities

Litigation Reform Act of 1995, we
provide the following cautionary remarks regarding important factors
that, among others, could cause future results
to differ materially from the forward-looking statements, expectations and assumptions
expressed or implied
herein.
All forward-looking statements made by us are subject to
risks and uncertainties and are not guarantees of
future performance.
These forward-looking statements involve known and unknown
risks, uncertainties and other
factors that may cause our actual results, performance and achievements
or industry results to be materially
different from any future results, performance or achievements expressed or implied by such
forward-looking
statements.
These statements are generally identified by the use of such
terms as “may,” “could,” “expect,”
“intend, “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,”
“to “to be,” “to make” or other comparable
terms.
Factors that could cause or contribute to such differences include, but are not limited
to, those discussed in
the documents we file with the Securities and Exchange Commission
(SEC), including our Annual Report on Form
10-K.
Forward looking statements include the overall impact of the Novel Coronavirus
Disease 2019 (COVID-19)
on the Company, its results of operations, liquidity, and financial condition (including any estimates of the impact
on these items), the rate and consistency with which dental and other practices
resume or maintain normal
operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”)
and COVID-19 related product sales and inventory levels and whether
additional resurgences or variants of the virus will
adversely impact the resumption of normal operations, the impact of restructuring
programs as well as of any future
acquisitions, and more generally current expectations regarding
performance in current and future periods.
Forward looking statements also include the (i) ability of the Company
to make additional testing available, the
nature of those tests and the number of tests intended to be made available
and the timing for availability, the nature
of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has
not
been, or will not have been, independently verified under normal FDA procedures
and (ii) potential for the
Company to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from

current and historical results
include, but are not limited to: risks associated with COVID-19
and any variants thereof, as well as other disease outbreaks, epidemics,
pandemics, or similar wide spread public health concerns and other natural
disasters or acts of terrorism; our
dependence on third parties for the manufacture and supply of our products;
our ability to develop or acquire and
maintain and protect new products (particularly technology products) and
technologies that achieve market
acceptance with acceptable margins; transitional challenges associated with acquisitions,
dispositions and joint
ventures, including the failure to achieve anticipated synergies/benefits; financial and tax
risks associated with
acquisitions, dispositions and joint ventures; certain provisions
in our governing documents that may discourage
third-party acquisitions of us; effects of a highly competitive (including, without limitation,
competition from third-
partythird-party online commerce sites) and consolidating market; the potential repeal or
judicial prohibition on
implementation of the Affordable Care Act; changes in the health care industry; risks from
expansion of customer
purchasing power and multi-tiered costing structures; increases in shipping costs
for our products or other service
issues with our third-party shippers; general global macro-economic and political
conditions, including
international trade agreements and potential trade barriers; failure to
comply with existing and future regulatory
requirements; risks associated with the EU Medical Device Regulation; failure
to comply with laws and regulations
relating to health care fraud or other laws and regulations; failure to comply with
laws and regulations relating to
the confidentiality of sensitive personal information or standards in electronic
health records or transmissions;
changes in tax legislation; litigation risks; new or unanticipated litigation
developments and the status of litigation
matters; cyberattacks or other privacy or data security breaches; risks associated
with our global operations; our
dependence on our senior management, as well as employee hiring and
retention; and disruptions in financial
markets. The order in which these factors appear should not be construed
to indicate their relative importance or priority.

priority.

34


33

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control

or predict.
Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction
of actual results.
We undertake no duty and have no obligation to update forward-looking statements.

Where You

Can Find Important Information

We may disclose important information through one or more of the following channels: SEC filings, public

conference calls and webcasts, press releases, the investor relations
page of our website (www.henryschein.com)
and the social media channels identified on the Newsroom page of our website.

Recent Developments

COVID-19 Pandemic

In March 2020, the World Health Organization declared COVID-19 a pandemic. The COVID-19 pandemic

negatively impacted the global economy, disrupted global supply chains and created significant volatility and
disruption of global financial markets. In response, many countries implemented
business closures and restrictions,
stay-at-home and social distancing ordinances and similar measures
to combat the pandemic, which significantly
impacted global business and dramatically reduced demand for dental
products and certain medical products in the
second quarter of 2020.
Demand increased in the second half of 2020 and continued into
the first quarterhalf of 2021,
resulting in growth over the prior year driven by sales of PPE and COVID-19
related products.

Our consolidated financial statements reflect estimates and assumptions

made by us that affect, among other things,
our goodwill, long-lived asset and indefinite-lived intangible asset valuation;
inventory valuation; equity investment
valuation; assessment of the annual effective tax rate; valuation of deferred income
taxes and income tax
contingencies; the allowance for doubtful accounts; hedging activity; vendor
rebates; measurement of
compensation cost for certain share-based performance awards and cash bonus
plans; and pension plan
assumptions.
Due to the significant uncertainty surrounding the future impact
of COVID-19, our judgments
regarding estimates and impairments could change in the future.
In addition, the impact of COVID-19 had a
material adverse effect on our business, results of operations and cash flows in the
second quarter of 2020. In the
latter half of
the second quarter of 2020, dental and medical practices began to re-open worldwide,
and continued to
do so during the second half of 2020.
During the first quarterhalf of 2021, patient traffic levels returned to levels
approaching pre-pandemic levels, although certain regions in the U.S. and
internationally are experiencing an
increase in COVID-19 cases.
levels. There is an ongoing risk that the COVID-19 pandemic may again
have a material
adverse effect on our business, results of operations and cash flows and may result in a
material adverse effect on
our financial condition and liquidity.
However, the extent of the potential impact cannot be reasonably estimated at
this time.

35


34

Executive-Level Overview

Henry Schein, Inc. is a solutions company for health care professionals powered

by a network of people and
technology. We
believe we are the world’s largest provider of health care products and services primarily to office-
basedoffice-based dental and medical practitioners, as well as alternate sites of care.
We serve more than one million customers
worldwide including dental practitioners and laboratories and physician practices,
as well as government,
institutional health care clinics and other alternate care clinics.
We believe that we have a strong brand identity due
to our more than 88 years of experience distributing health care products.

We are headquartered in Melville, New York,

employ more than 20,000approximately 21,000 people (of which more than 9,50010,200 are
based outside the United States) and have operations or affiliates in 3132 countries and territories,
including the
United States, Australia, Austria, Belgium, Brazil, Canada, Chile, China,
the Czech Republic, France, Germany,
Hong Kong SAR, Ireland, Israel, Italy, Japan, Liechtenstein, Luxembourg, Malaysia, Mexico, the Netherlands, New
Zealand, Poland, Portugal, Singapore, South Africa, Spain, Sweden, Switzerland,
Thailand, United Arab Emirates
and the United Kingdom.

We have established strategically located distribution centers around the world to enable us to better serve our

customers and increase our operating efficiency.
This infrastructure, together with broad product and service
offerings at competitive prices, and a strong commitment to customer service, enables
us to be a single source of
supply for our customers’ needs.
Our infrastructure also allows us to provide convenient ordering and
rapid,
accurate and complete order fulfillment.

We conduct our business

through two reportable segments: (i) health care distribution and
(ii) technology and
value-added services.
These segments offer different products and services to the same customer base.

The health care distribution reportable segment aggregates our global dental

and medical operating segments.
This
segment distributes consumable products, small equipment, laboratory products,
large equipment, equipment repair
services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic
tests, infection-control
products and vitamins.
Our global dental group serves office-based dental practitioners, dental laboratories, schools
and other institutions.
Our global medical group serves office-based medical practitioners, ambulatory
surgery
centers, other alternate-care settings and other institutions.

Our global technology and value-added services group provides software,

technology and other value-added
services to health care practitioners.
Our technology group offerings include practice management software
systems for dental and medical practitioners.
Our value-added practice solutions include financial services on a
non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education
services for practitioners.

Industry Overview

In recent years, the health care industry has increasingly focused on cost containment.

This trend has benefited
distributors capable of providing a broad array of products and services at low
prices.
It also has accelerated the
growth of HMOs, group practices, other managed care accounts and collective buying
groups, which, in addition to
their emphasis on obtaining products at competitive prices, tend to favor distributors
capable of providing
specialized management information support.
We believe that the trend towards cost containment has the potential
to favorably affect demand for technology solutions, including software, which can
enhance the efficiency and
facilitation of practice management.

Our operating results in recent years have been significantly affected by strategies

and transactions that we
undertook to expand our business, domestically and internationally, in part to address significant changes in the
health care industry, including consolidation of health care distribution companies, health care reform, trends
toward managed care, cuts in Medicare and collective purchasing arrangements.

Our current and future results have been and could be impacted by the COVID-19

pandemic, the current economic
environment and continued economic and public health uncertainty.
Since the onset of the COVID-19 pandemic in
early 2020, we have been carefully monitoring its impact on our global
operations and have taken appropriate steps

36


35

to minimize the risk to our employees. We have seen and continue to see changes in demand trends for some of our

products and services as rates of infection fluctuate, new strains or mutations
variants of COVID-19 emerge and spread,
vaccine uptake increases, governments adapt their approaches to combatting
the virus, and local conditions change
across geographies. As a result, we expect to see continued volatility through
at least the duration of the pandemic.

Industry Consolidation

The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented

and diverse.
The industry ranges from sole practitioners working out of
relatively small offices to group practices
or service organizations ranging in size from a few practitioners to a large number of practitioners who have
combined or otherwise associated their practices.

Due in part to the inability of office-based health care practitioners to store and manage

large quantities of supplies
in their offices, the distribution of health care supplies and small equipment to office-based health
care practitioners
has been characterized by frequent, small quantity orders, and a need for rapid,
reliable and substantially complete
order fulfillment.
The purchasing decisions within an office-based health care practice are typically
made by the
practitioner or an administrative assistant.
Supplies and small equipment are generally purchased from more
than
one distributor, with one generally serving as the primary supplier.

The trend of consolidation extends to our customer base.

Health care practitioners are increasingly seeking to
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician
hospital organizations.
In many cases, purchasing decisions for consolidated groups
are made at a centralized or
professional staff level; however, orders are delivered to the practitioners’ offices.

We believe that consolidation within the industry will continue to result in a number of distributors, particularly

those with limited financial, operating and marketing resources, seeking to
combine with larger companies that can
provide growth opportunities.
This consolidation also may continue to result in distributors seeking
to acquire
companies that can enhance their current product and service offerings or provide
opportunities to serve a broader
customer base.

Our trend with regard to acquisitions and joint ventures has been to expand

our role as a provider of products and
services to the health care industry.
This trend has resulted in our expansion into service areas that complement
our
existing operations and provide opportunities for us to develop synergies with, and
thus strengthen, the acquired
businesses.

As industry consolidation continues, we believe that we are positioned

to capitalize on this trend, as we believe we
have the ability to support increased sales through our existing infrastructure, although
there can be no assurances
that we will be able to successfully accomplish this.
We also have invested in expanding our sales/marketing
infrastructure to include a focus on building relationships with decision
makers who do not reside in the office-
basedoffice-based practitioner setting.

As the health care industry continues to change, we continually evaluate possible

candidates for merger and joint
venture or acquisition and intend to continue to seek opportunities to expand
our role as a provider of products and
services to the health care industry.
There can be no assurance that we will be able to successfully pursue
any such
opportunity or consummate any such transaction, if pursued.
If additional transactions are entered into or
consummated, we would incur merger and/or acquisition-related costs, and there
can be no assurance that the
integration efforts associated with any such transaction would be successful.
In response to the COVID-19
pandemic, we had taken a range of actions to preserve cash, including
the temporary suspension of significant
acquisition activity.
During the second half of 2020, as global conditions improved, we
resumed our acquisition strategy.

strategy.

37


36

Aging Population and Other Market Influences

The health care products distribution industry continues to experience growth

due to the aging population,
increased health care awareness, the proliferation of medical technology
and testing, new pharmacology treatments
and expanded third-party insurance coverage, partially offset by the effects of unemployment on insurance
coverage. In addition, the physician market continues to benefit from the shift
of procedures and diagnostic testing
from acute care settings to alternate-care sites, particularly physicians’
offices.

According to the U.S. Census Bureau’s International Data Base, in 20202021 there were more than six and a half million

Americans aged 85 years or older, the segment of the population most in need of long-term care
and elder-care
services. By the year 2050, that number is projected to nearly triple to approximately
19 million. The population
aged 65 to 84 years is projected to increase by approximately 36%32% during
the same time period.

As a result of these market dynamics, annual expenditures for health

care services continue to increase in the
United States. We believe that demand for our products and services will grow, while continuing to be impacted by
current and future operating, economic and industry conditions. The Centers
for Medicare and Medicaid Services,
or CMS, published “National Health Expenditure Projections 2019-2028”
indicating that total national health care
spending reached approximately $3.8 trillion in 2019, or 17.7% of
the nation’s gross domestic product, the
benchmark measure for annual production of goods and services in the United
States. Health care spending is
projected to reach approximately $6.2 trillion in 2028, approximately 19.7% of
the nation’s projected gross
domestic product.

Government

Certain of our businesses involve the distribution, importation, exportation,

marketing and sale of, and third party
payment for, pharmaceuticals and medical devices, and in this regard, we are subject to extensive local, state,
federal and foreign governmental laws and regulations, including as applicable
to our wholesale distribution of
pharmaceuticals and medical devices, and as part of our specialty home medical supply
business that distributes and
sells medical equipment and supplies directly to patients.
The federal government and state governments have also
increased enforcement activity in the health care sector, particularly in areas of fraud and abuse, anti-bribery
and
corruption, controlled substances handling,
medical device regulations, and data privacy and security standards.

Government and private insurance programs fund a large portion of the total cost of medical care,

and there have
been efforts to limit such private and government insurance programs, including efforts,
thus far unsuccessful, to
seek repeal of the entire United States Patient Protection and Affordable Care Act,
as amended by the Health Care
and Education Reconciliation Act, each enacted in March 2010, as amended.
In addition, activities to control
medical costs, including laws and regulations lowering reimbursement rates
for pharmaceuticals, medical devices,
and/or medical treatments or services, are ongoing.
Many of these laws and regulations are subject to change
and
their evolving implementation may impact our operations and our
financial performance.

Our businesses are also generally subject to numerous other laws and regulations

that could impact our financial
performance, including securities, antitrust, consumer protection, anti-bribery
and anti-kickback, customer
interaction transparency, data privacy,
data security, government contracting,
price gouging, and other laws and
regulations.

Failure to comply with law or regulations could have a material adverse effect on our business.

A more detailed

discussion of governmental laws and regulations is included in Management’s Discussion & Analysis, contained

38


in
our Annual Report on Form 10-K for the fiscal year ended December 26,
2020, filed on February 17, 2021.
37

Results of Operations

The following table summarizes the significant components of our operating

results for the three and six months ended June 26, 2021 and June 27, 2020 and cash flows for the three
six months ended March 27,June 26, 2021 and March 28,June 27, 2020 (in thousands):

 

 

 

 

Three Months Ended

 

Six Months Ended

 

 

 

 

June 26,

 

June 27,

 

June 26,

 

June 27,

 

 

 

 

2021

 

2020

 

2021

 

2020

Operating results:

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

 

$

2,967,223

 

$

1,684,399

 

$

5,892,184

 

$

4,113,270

Cost of sales

 

 

2,077,472

 

 

1,230,133

 

 

4,111,582

 

 

2,912,990

 

Gross profit

 

 

889,751

 

 

454,266

 

 

1,780,602

 

 

1,200,280

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

678,801

 

 

445,765

 

 

1,336,793

 

 

1,013,127

 

Restructuring costs

 

 

604

 

 

15,934

 

 

3,535

 

 

20,721

 

 

Operating income (loss)

 

$

210,346

 

$

(7,433)

 

$

440,274

 

$

166,432

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Other expense, net

 

$

(4,665)

 

$

(8,780)

 

$

(8,858)

 

$

(13,622)

Net income (loss) from continuing operations

 

 

163,977

 

 

(13,852)

 

 

338,905

 

 

119,995

Income from discontinued operations

 

 

-

 

 

585

 

 

-

 

 

303

Net income (loss) attributable to Henry Schein, Inc.

 

 

155,716

 

 

(10,797)

 

 

321,713

 

 

119,464

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended

 

 

 

 

 

 

 

 

 

 

June 26,

 

June 27,

 

 

 

 

 

 

 

 

 

 

2021

 

2020

Cash flows:

 

 

 

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities from continuing operations

 

$

221,726

 

$

(12,843)

Net cash used in investing activities from continuing operations

 

 

(341,119)

 

 

(69,641)

Net cash provided by (used in) financing activities from continuing operations

 

 

(139,395)

 

 

262,050

Three Months Ended
March 27,
March 28,
2021
2020
Operating results:
Net sales
$
2,924,961
$
2,428,871
Cost of sales
2,034,110
1,682,857
Gross profit
890,851
746,014
Operating expenses:
Selling, general and administrative
657,992
567,362
Restructuring costs
2,931
4,787
Operating income
$
229,928
$
173,865
Other expense, net
$
(4,193)
$
(4,842)
Net income from continuing operations
174,928
133,847
Loss from discontinued operations
-
(282)
Net income attributable to Henry Schein, Inc.
165,997
130,261
Three Months Ended
March 27,
March 28,
2021
2020
Cash flows:
Net cash provided by operating activities from continuing operations
$
63,331
$
78,757
Net cash used in investing activities from continuing operations
(223,244)
(53,605)
Net cash provided by (used in) financing activities from continuing operations
(119,444)
491,608

Plans of Restructuring

On November 20, 2019, we committed to a contemplated initiative, intended

to mitigate stranded costs associated
with the Animal Health Spin-off and to rationalize operations and to provide expense
efficiencies.
These activities
were originally expected to be completed by the end of 2020.
In light of the changes to the business environment
brought on by the COVID-19 pandemic, we extended such activities
to the end of 2021.

During the three months ended March 27,June 26, 2021 and March 28,June 27, 2020, we

recorded restructuring costs of $2.9
$0.6 million and $4.8$15.9 million. During the six months ended June 26, 2021 and June 27, 2020, we recorded restructuring costs of $3.5 million respectively.and $20.7 million. The restructuring costs for these periods included costs for severance
benefits and facility exit costs.
The costs associated with these restructurings are included in
a separate line item,
“Restructuring “Restructuring costs” within our consolidated statements of income.

We are currently unable in good faith to make a determination of an estimate of the amount or range of

amounts expected to be incurred in connection with these activities
in 2021, both with respect to each major type of
cost associated therewith and with respect to the total cost, or an estimate
of the amount or range of amounts that
will result in future cash expenditures.

39


38

Three Months Ended March 27,June 26, 2021 Compared to Three Months Ended March 28,June 27, 2020

Net Sales

Net sales for the three months ended March 27,June 26, 2021 and March 28,June 27, 2020 were

as follows (in thousands):

 

 

 

 

June 26,

 

% of

 

June 27,

 

% of

 

Increase / (Decrease)

 

 

 

 

2021

 

Total

 

2020

 

Total

 

$

 

%

Health care distribution (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dental

 

$

1,910,344

 

64.4

%

 

$

941,292

 

55.9

%

 

$

969,052

 

102.9

%

 

Medical

 

 

904,828

 

30.5

 

 

 

617,810

 

36.7

 

 

 

287,018

 

46.5

 

 

 

Total health care distribution

 

 

2,815,172

 

94.9

 

 

 

1,559,102

 

92.6

 

 

 

1,256,070

 

80.6

 

Technology and value-added services (2)

 

 

152,051

 

5.1

 

 

 

105,227

 

6.2

 

 

 

46,824

 

44.5

 

 

 

Total excluding Corporate TSA revenue

 

 

2,967,223

 

100.0

 

 

 

1,664,329

 

98.8

 

 

 

1,302,894

 

78.3

 

Corporate TSA revenue (3)

 

 

-

 

-

 

 

 

20,070

 

1.2

 

 

 

(20,070)

 

-

 

 

 

Total

 

$

2,967,223

 

100.0

%

 

$

1,684,399

 

100.0

%

 

$

1,282,824

 

76.2

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 27,
% of
March 28,
% of
Increase / (Decrease)
2021
Total
2020
Total
$
%
Health care distribution

(1)

Dental
$
1,788,928
61.2
%
$
1,475,076
60.7
%
$
313,852
21.3
%
Medical
993,037
33.9
800,688
33.0
192,349
24.0
Total health care distribution
2,781,965
95.1
2,275,764
93.7
506,201
22.2
Technology and value-added services
(2)
142,996
4.9
131,965
5.4
11,031
8.4
Total excluding Corporate TSA revenue
2,924,961
100.0
2,407,729
99.1
517,232
21.5
Corporate TSA revenue
(3)
-
-
21,142
0.9
(21,142)
-
Total
$
2,924,961
100.0
%
$
2,428,871
100.0
%
$
496,090
20.4
(1)
Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and
generic
pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment
and vitamins.

(2)

Consists of practice management software and other value-added products, which are distributed primarily to health care providers,
and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other
services.

(3)

Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in
connection with
the Animal Health Spin-off, which ended in December 2020.
See
for further information.

information.

The 20.4%76.2% increase in net sales for the three months ended March 27,June 26, 2021

includes an increase of 18.2%71.0% in local
currency revenue (14.9%(65.5% increase in internally generated revenue and 3.3%
5.5% growth from acquisitions) and an
increase of 2.2%5.2% related to foreign currency exchange.
During December 2020, our previous transition services
agreement (TSA) with Covetrus, in connection with the completion of the Animal-Health
Spin-off, concluded.
Accordingly, we recorded no Corporate TSA revenues for the three months ended March 27,June 26, 2021.
Sales for the
three months ended March 27,June 26, 2021 benefited from sales of PPE and COVID-19
related products of approximately
$457.5 $354.2 million, an increase of approximately 189.5%
76.0% versus the prior year.
Excluding PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 66.2%. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. On a comparable basis to the three months ended June 29, 2019, our net sales for the three months ended June 26, 2021 increased by 15.2% in local currency.

The 21.3%102.9% increase in dental net sales for the three months ended

March 27, June 26, 2021 includes an increase of 17.9%94.3% in
local currency revenue (13.7%(87.0% increase in internally generated revenue
and 4.2%7.3% growth from acquisitions) and an
increase of 3.4%8.6% related to foreign currency exchange.
The 17.9%94.3% increase in local currency sales was attributable
to an increase in dental consumable merchandise sales of 18.3% (13.2%
99.7% (90.5% increase in internally generated revenue
and 5.1%9.2% growth from acquisitions)
and an increase in dental equipment sales and service revenues
of 16.1%76.3%,
(15.5% (75.3% increase in internally generated revenue and 0.6%1.0% growth from acquisitions).
The COVID-19 pandemic
had an adverse impact on prior year revenues when dental offices began closing or
seeing a limited number of
patients beginning in mid-March of 2020.
However, in the second half of the quarter ended June 27, 2020 our dental sales began to improve as dental practices began to resume activities and patient traffic increased. During the firstsecond quarter of 2021, patient traffic levels returnedcontinued to
return to levels
approaching pre-pandemic levels, thus contributing to growth in worldwide dental
revenues. Additionally, global
dental sales for the three months ended March 27,June 26, 2021 benefited from sales
of PPE and COVID-19 related
products of approximately $169.3$181.8 million, an increase of approximately
72.4%
87.6% versus the prior year.
Excluding
PPE and COVID-19 related products, the increase in internally generated
local currency dental sales was 11.9%90.8%. On a comparable basis to the three months ended June 29, 2019, our dental net sales for the three months ended June 26, 2021 increased by 12.1% in local currency.

40


The 24.0%46.5% increase in medical net sales for the three months ended

March 27, June 26, 2021 includes an increase of 23.7%
46.1% in local currency revenue (22.1%(43.5% increase in internally generated
revenue and 1.6%
2.6% growth from acquisitions)
and
an increase of 0.3%0.4% related to foreign currency exchange.
The COVID-19 pandemic began to adversely impact our medical revenue beginning in mid-March 2020 and in the first half of the second quarter of 2020, as many medical offices closed or saw a limited number of patients. Economic conditions relating to the COVID-19
pandemic had less of an impact on the performance of our
medical group in the prior year in part due to continued
strong sales of PPE, such as masks, gowns and face shields, and other COVID-19
related products.
Globally, our
products, which have continued to be strong in the current year. Our medical business continued to benefit fromrecorded sales of $172.4 million of such PPE and other
COVID-19 related products for the three
months ended March 27,June 26, 2021, recording net sales of $288.2 million,
an increase of approximately 381.3%
65.3% compared to the prior year.
Excluding sales of PPE and other COVID-19 related products, medical
internal sales in
local currencies was down 6.8%,increased by 39.1%. On a comparable basis to the three months ended June 29, 2019, our medical net sales for the three months ended June 26, 2021 increased by 27.2% in part due to a mild influenza season that impacted
diagnostic and consumable
merchandise sales, as well as from lower pharmaceutical sales.
39
local currency.

The 8.4%44.5% increase in technology and value-added services net sales for the

three months ended March 27,June 26, 2021
includes an increase of 7.0%
41.9% local currency revenue (3.6%(33.0% increase in internally generated revenue
and 3.4%
8.9% growth from acquisitions) and an increase of 1.4%
2.6% related to foreign currency exchange.
Sales growth was driven
by our practice management business, as well as strong financial services
revenue, which benefited from dental
equipment sales growth.
During the quarter ended March 27,June 26, 2021, the trend for transactional
software revenues
improved compared to the prior year, as more patients visited dental practices worldwide. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted transactional software revenues. On a comparable basis to the three months ended June 29, 2019, our technology and value-added services net sales for the three months ended June 26, 2021 increased by 10.1% in local currency.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the three months

ended March 27,June 26, 2021 and
March 28, June 27, 2020 were as follows (in thousands):

 

 

 

June 26,

 

Gross

 

June 27,

 

Gross

 

Increase / (Decrease)

 

 

 

2021

 

Margin %

 

2020

 

Margin %

 

$

 

%

Health care distribution

 

$

784,841

 

27.9

%

 

$

381,042

 

24.4

%

 

$

403,799

 

106.0

%

Technology and value-added services

 

 

104,910

 

69.0

 

 

 

72,683

 

69.1

 

 

 

32,227

 

44.3

 

 

Total excluding Corporate TSA revenues

 

 

889,751

 

30.0

 

 

 

453,725

 

27.3

 

 

 

436,026

 

96.1

 

Corporate TSA revenues

 

 

-

 

-

 

 

 

541

 

2.7

 

 

 

(541)

 

-

 

 

Total

 

$

889,751

 

30.0

 

 

$

454,266

 

27.0

 

 

$

435,485

 

95.9

 

March 27,
Gross
March 28,
Gross
Increase / (Decrease)
2021
Margin %
2020
Margin %
$
%
Health care distribution
$
789,984
28.4
%
$
653,316
28.7
%
$
136,668
20.9
%
Technology and value-added services
100,867
70.5
92,085
69.8
8,782
9.5
Total excluding Corporate TSA revenues
890,851
30.5
745,401
31.0
145,450
19.5
Corporate TSA revenues
-
-
613
2.9
(613)
-
Total
$
890,851
30.5
$
746,014
30.7
$
144,837
19.4

As a result of different practices of categorizing costs associated with distribution networks

throughout our
industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we
realize substantially higher gross margin percentages in our technology segment than in
our health care distribution
segment. These higher gross margins result from being both the developer and
seller of software products and
services, as well as certain financial services. The software industry
typically realizes higher gross margins to
recover investments in research and development.

During December 2020, our previous transition services agreement with

Covetrus, in connection with the
completion of the Animal-Health Spin-off, concluded.
Under this agreement, Covetrus had agreed to purchase
certain products from us at a mark-up that ranged from 3% to 6% of our product
cost to cover handling costs.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in

the mix of products sold as well as changes in our customer mix have
been the most significant drivers affecting
our gross profit margin. For example, sales of pharmaceutical products are generally
at lower gross profit margins
than other products. Conversely, sales of our private label products achieve gross profit margins that are higher than
average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross
margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners,
who
normally purchase lower volumes at greater frequencies.

41


Health care distribution gross profit increased $136.7$403.8 million, or 20.9%106.0%, for

the three months ended March 27,June 26, 2021
compared to the prior year period, due primarily to the increase in net sales
discussed above.
Health care
distribution gross profit margin decreasedincreased to 28.4%27.9% for the three months ended March 27,
June 26, 2021 from 28.7%24.4% for the
comparable prior year period due primarily to lower adjustments recorded for PPE inventory. Such adjustments to inventory
and COVID-19 related products, as
well as influenza diagnostic kits, caused by volatility of pricing and demand
experienced during the quarter.
Such
conditions may recur and adversely impact gross profit margins in future periods,
although we do not expect further
material inventory adjustments in 2021.
The increase in health care distribution gross profit margin is also attributable to an increase in vendor rebates during the second quarter of 2021 due to increased purchase volumes. The overall increase in our health care distribution gross profit
is
attributable to an increase of $120.5$298.9 million from internally generated
revenue, and $27.2a $78.3 million increase in gross
profit from acquisitions, partially offset by an $11.0 million decline in gross profit due to the decrease
increase in the gross
margin rates.
40
rates and a $26.6 million increase in gross profit from acquisitions.

Technology and value-added services gross profit increased $8.8$32.2 million, or 9.5%44.3%, for the three months ended

March 27, June 26, 2021 compared to the prior year period.
The overall increase in our Technology and value-added
services gross profit is attributable to a $4.5$25.8 million increase in internally
generated revenue $4.2and $6.8 million additional
gross profit from acquisitions,
and an increase partially offset by a decrease of $0.1$0.4 million from gross margin rates.
Technology and value-
addedvalue-added services gross profit margin increaseddecreased to 70.5%69.0% for the three months ended March 27,June 26, 2021
from 69.8%69.1% for
the comparable prior year period primarily due to an increase in the volume ofperiod.

our transactional revenue from
eClaims and credit card processing.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in

total for the three months ended MarchJune 26, 2021 and June 27, 2021
and March 28, 2020 were as follows (in thousands):

 

 

 

 

 

 

% of

 

 

 

 

% of

 

 

 

 

 

 

 

 

 

June 26,

 

Respective

 

June 27,

 

Respective

 

Increase

 

 

 

2021

 

Net Sales

 

2020

 

Net Sales

 

$

 

%

Health care distribution

 

$

603,080

 

21.4

%

 

$

406,931

 

26.1

%

 

$

196,149

 

48.2

%

Technology and value-added services

 

 

76,325

 

50.2

 

 

 

54,768

 

52.0

 

 

 

21,557

 

39.4

 

 

Total

 

$

679,405

 

22.9

 

 

$

461,699

 

27.4

 

 

$

217,706

 

47.2

 

% of
% of
March 27,
Respective
March 28,
Respective
Increase
2021
Net Sales
2020
Net Sales
$
%
Health care distribution
$
592,052
21.3
%
$
505,762
22.2
%
$
86,290
17.1
%
Technology and value-added services
68,871
48.2
66,387
50.3
2,484
3.7
Total
$
660,923
22.6
$
572,149
23.6
$
88,774
15.5

Selling, general and administrative expenses (including restructuring costs

in the three months ended March 27,
June 26, 2021 and March 28,June 27, 2020) increased $88.8$217.7 million, or 15.5%47.2%, for the three
months ended March 27,June 26, 2021 from the
comparable prior year period.
In the prior year, there were significant cost-saving measures taken in response to the COVID-19 pandemic. These cost-saving measures were temporary and substantially ended during the second half of 2020.

The $86.3$196.1 million increase in selling, general and administrative expenses

within our
health care distribution segment for the three months ended March 27, 2021
as compared to the prior year period
was attributable to an increase of $64.8 million of operating costs (including
$12.8 million of settlement and
litigation costs), an increase of $23.3 million of additional
costs from acquired companies, partially offset by a
decrease of $1.8 million in restructuring costs.
The $2.5 million increase in selling, general and administrative
expenses within our technology and value-added services segment for the three
months ended March 27,June 26, 2021 as
compared to the prior year period was attributable to an increase of $3.5
$186.7 million of operating costs and an increase of $24.4 million of additional costs from acquired
companies, partially offset by a decrease of $1.0$15.0 million in restructuring costs. The $21.6million increase in selling, general and administrative expenses within our technology and value-added services segment for the three months ended June 26, 2021 as compared to the prior year period was attributable to an increase of $16.2 million of operating costs and an increase of $5.8 million of additional costs from acquired companies, partially offset by a decrease of $0.4 million in restructuring costs.
As a percentage of net sales, selling,
general and administrative expenses decreased to 22.6%22.9% from 23.6%27.4% for
the comparable prior year period.
period, primarily due to the increased sales base.

As a component of total selling, general and administrative expenses, selling

expenses increased $12.9$151.3 million, or
3.5% 58.5% to $384.7$409.8 million, for the three months ended March 27, 2021 from
the comparable prior year period.
As a
percentage of net sales, selling expenses decreased to 13.2% from 15.3%
for the comparable prior year period.
As a component of total selling, general and administrative expenses, general
and administrative expenses
increased $75.9 million, or 37.9% to $276.2 million, for the three months
ended March 27,June 26, 2021 from the
comparable prior year period primarily due to an increase in payroll and payroll
related costs.
As a percentage of
net sales, general
and administrativeselling expenses increaseddecreased to 9.4%13.8% from 8.2%15.3% for the
comparable prior year period.period, primarily due to the increased sales base.

42


Our

As a component of total selling, general and administrative expenses, for the three months

ended March 28, 2020 were affected by
certain estimates we made duegeneral and administrative expenses increased $66.4 million, or 32.7% to the adverse business environment brought
on by the COVID-19 pandemic.
For
example, in the prior-year quarter we recorded incremental bad debt reserves of approximately
$10$269.6 million, for our
global dental business. We also recognized a net credit of approximately $17.5 million in stock-based compensation
expense during the prior-year quarter as we had estimated that no performance shares granted
in 2018, 2019 or
2020 would ultimately vest. In contrast, for the three months ended March
27,June 26, 2021 we recorded $12.8 millionfrom the comparable prior year period, primarily due to an increase in
stock-based compensation expense.
Additionally, in payroll and payroll related costs. As a percentage of net sales, general and administrative expenses decreased to 9.1% from 12.1% for the prior-year quarter we recorded total impairment charges of
approximately $6.1 million duringcomparable prior year period, primarily due to the quarter related to prepaid royaltyincreased sales base.

expenses and a customer relationship
intangible asset. We recorded no such impairment charges in the three months ended March 27, 2021.
41

Other Expense, Net

Other expense, net, for the three months ended March 27,June 26, 2021 and March

28,June 27, 2020 was as follows (in thousands):

 

 

 

June 26,

 

June 27,

 

Variance

 

 

 

2021

 

2020

 

$

 

%

Interest income

 

$

1,357

 

$

1,997

 

$

(640)

 

(32.0)

%

Interest expense

 

 

(6,376)

 

 

(10,486)

 

 

4,110

 

39.2

 

Other, net

 

 

354

 

 

(291)

 

 

645

 

221.6

 

 

Other expense, net

 

$

(4,665)

 

$

(8,780)

 

$

4,115

 

46.9

 

March 27,
March 28,
Variance
2021
2020
$
%
Interest income
$
1,983
$
3,190
$
(1,207)
(37.8)
%
Interest expense
(6,485)
(7,812)
1,327
17.0
Other, net
309
(220)
529
240.5
Other expense, net
$
(4,193)
$
(4,842)
$
649
13.4

Interest income decreased $1.2$0.6 million primarily due to lower investment

interest rates and reduced late fee income.
Interest expense
decreased $1.3$4.1 million primarily due to decreasedreduced credit line borrowings under our
bank credit lines as well asand lower interest rates on certain of our private placement borrowings.

rates.

Income Taxes

For the three months ended March 27,June 26, 2021, our effective tax rate was 25.1%23.4% compared

to 22.4%5.9% for the prior year
period.
The difference between our effective tax rate and the federal statutory tax rate for the
three months ended
March 27, June 26, 2021, was primarily due to state and foreign income taxes, interest expense and interest
expense.
tax charges and credits associated with legal entity reorganizations. The difference between
our effective tax rate and the federal statutory tax rate for the three months ended
March 28, June 27, 2020, primarily relates
to state and foreign income taxes and interest expensea valuation allowance recognized on a portion of a deferred tax asset. Further, our effective tax rate was distorted due to our low pretax loss during the second quarter ended June 27, 2020.

43


Six Months Ended June 26, 2021 Compared to Six Months Ended June 27, 2020

Net Sales

Net sales for the six months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

 

 

 

 

June 26,

 

% of

 

June 27,

 

% of

 

Increase/(Decrease)

 

 

 

 

2021

 

Total

 

2020

 

Total

 

$

 

%

Health care distribution (1)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Dental

 

$

3,699,272

 

62.8

%

 

$

2,416,368

 

58.7

%

 

$

1,282,904

 

53.1

%

 

Medical

 

 

1,897,865

 

32.2

 

 

 

1,418,498

 

34.5

 

 

 

479,367

 

33.8

 

 

 

Total health care distribution

 

 

5,597,137

 

95.0

 

 

 

3,834,866

 

93.2

 

 

 

1,762,271

 

46.0

 

Technology and value-added services (2)

 

 

295,047

 

5.0

 

 

 

237,192

 

5.8

 

 

 

57,855

 

24.4

 

 

 

Total excluding Corporate TSA revenue

 

 

5,892,184

 

100.0

 

 

 

4,072,058

 

99.0

 

 

 

1,820,126

 

44.7

 

Corporate TSA revenue (3)

 

 

-

 

-

 

 

 

41,212

 

1.0

 

 

 

(41,212)

 

-

 

 

 

Total

 

$

5,892,184

 

100.0

%

 

$

4,113,270

 

100.0

%

 

$

1,778,914

 

43.2

 

(1)Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment and vitamins.

(2)Consists of practice management software and other value-added products, which are distributed primarily to health care providers, and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services.

(3)Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health Spin-off, which ended in December 2020. See Note-18 Related Party Transactions for further information.

The 43.2% increase in net sales for the six months ended June 26, 2021 includes an increase of 39.8% in local currency revenue (35.6% increase in internally generated revenue and 4.2% growth from acquisitions) and an increase of 3.4% related to foreign currency exchange. Excluding sales of products under the transition services agreement with Covetrus, our net sales increased 44.7%, including an increase in local currency revenue of 41.2% (37.0% increase in internally generated revenue and 4.2% growth from acquisitions) and an increase of 3.5% related to foreign currency exchange. Sales for the six months ended June 26, 2021 benefited from sales of PPE and COVID-19 related products of approximately $811.7 million, an increase of 125.9% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency sales was 28.8%. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted global business and dramatically reduced demand for dental products and certain medical products in the second quarter of 2020. On a comparable basis to the six months ended June 29, 2019, our net sales for the six months ended June 26, 2021 increased by 16.3% in local currency.

The 53.1% increase in dental net sales for the six months ended June 26, 2021 includes an increase of 47.6% local currency revenue (42.2% increase in internally generated revenue and 5.4% growth from acquisitions) and an increase of 5.5% related to foreign currency exchange. The 47.6% increase in local currency sales was attributable to an increase in dental consumable merchandise revenue of 49.4% (42.7% increase in internally generated revenue and 6.7% growth from acquisitions), and an increase in dental equipment sales and service revenues of 41.1% (40.4% increase in internally generated revenue and 0.7% growth from acquisitions). The COVID-19 pandemic began to adversely impact our worldwide dental revenue beginning in mid-March of 2020 as many dental offices progressively closed or began seeing a limited number of patients. However, in the second half of the quarter ended June 27, 2020 and continuing through the second quarter of 2021 patient traffic levels returned to levels approaching pre-pandemic levels, thus contributing to growth in worldwide dental revenues. Additionally, global dental sales for the six months ended June 26, 2021 benefited from sales of PPE and COVID-19 related products of approximately $351.1 million, an increase of 80.0% versus the prior year. Excluding PPE and COVID-19 related products, the increase in internally generated local currency dental sales was 41.9%. On a comparable basis to the six months ended June 29, 2019, our dental net sales for the six months ended June 26, 2021 increased by 10.7% in local currency.

44


The 33.8% increase in medical net sales for the six months ended June 26, 2021 is attributable to an increase of 33.5% local currency growth (31.4% increase in internally generated revenue and 2.1% growth from acquisitions) and an increase of 0.3% related to foreign currency exchange. Economic conditions relating to the COVID-19 pandemic have had less of an impact on the performance of our medical group versus dental, in part due to continued strong sales of PPE, such as masks, gowns and face shields, and other COVID-19 related products, such as diagnostic test kits. Globally, our medical business recorded sales of $460.6 million sales of such PPE and other COVID-19 related products for the six months ended June 26, 2021, an increase of approximately 180.5% compared to the prior year. Excluding sales of PPE and other COVID-19 related products, medical internal sales in local currencies increased by 12.0%. On a comparable basis to the six months ended June 29, 2019, our medical net sales for the six months ended June 26, 2021 increased by 33.3% in local currency.

The 24.4% increase in technology and value-added services net sales for the six months ended June 26, 2021 is attributable to an increase of 22.5% in local currency revenue (16.7% increase in internally generated revenue and 5.8% growth from acquisitions) and 1.9% related to foreign currency exchange. Sales growth was driven by our practice management business, as well as strong financial services revenue, which benefitted from dental equipment sales growth. Net sales in the prior year were adversely affected by the COVID-19 pandemic, which significantly impacted transactional software revenues. On a comparable basis to the six months ended June 29, 2019, our technology and value-added services net sales for the six months ended June 26, 2021 increased by 10.4% in local currency.

Gross Profit

Gross profit and gross margin percentages by segment and in total for the six months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

 

 

 

June 26,

 

Gross

 

June 27,

 

Gross

 

Increase/(Decrease)

 

 

 

2021

 

Margin %

 

2020

 

Margin %

 

$

 

%

Health care distribution

 

$

1,574,825

 

28.1

%

 

$

1,034,358

 

27.0

%

 

$

540,467

 

52.3

%

Technology and value-added services

 

 

205,777

 

69.7

 

 

 

164,768

 

69.5

 

 

 

41,009

 

24.9

 

 

Total excluding Corporate TSA revenues

 

 

1,780,602

 

30.2

 

 

 

1,199,126

 

29.4

 

 

 

581,476

 

48.5

 

Corporate TSA revenues

 

 

-

 

-

 

 

 

1,154

 

2.8

 

 

 

(1,154)

 

-

 

 

Total

 

$

1,780,602

 

30.2

 

 

$

1,200,280

 

29.2

 

 

$

580,322

 

48.3

 

As a result of different practices of categorizing costs associated with distribution networks throughout our industry, our gross margins may not necessarily be comparable to other distribution companies. Additionally, we realize substantially higher gross margin percentages in our technology and value-added services segment than in our health care distribution segment. These higher gross margins result from being both the developer and seller of software products and services, as well as certain financial services. The software industry typically realizes higher gross margins to recover investments in research and development.

During December 2020, our previous transition services agreement with Covetrus, in connection with the completion of the Animal-Health Spin-off, concluded. Under this agreement, Covetrus had agreed to purchase certain products from us at a mark-up that ranged from 3% to 6% of our product cost to cover handling costs.

Within our health care distribution segment, gross profit margins may vary from one period to the next. Changes in the mix of products sold as well as changes in our customer mix have been the most significant drivers affecting our gross profit margin. For example, sales of our private label products achieve gross profit margins that are higher than average. With respect to customer mix, sales to our large-group customers are typically completed at lower gross margins due to the higher volumes sold as opposed to the gross margin on sales to office-based practitioners, who normally purchase lower volumes at greater frequencies.

45


Health care distribution gross profit increased $540.5 million, or 52.3%, for the six months ended June 26, 2021 compared to the prior year period. Health care distribution gross profit margin increased to 28.1% for the six months ended June 26, 2021 from 27.0% for the comparable prior year period, primarily due to lower adjustments recorded for PPE inventory. Such adjustments to inventory may recur and adversely impact gross profit margins in future periods, although we do not expect further material inventory adjustments in 2021. The increase in the health care distribution gross profit margin is also attributable to an increase in vendor rebates during the first six months of 2021 due to increased purchase volumes. The overall increase in our health care distribution gross profit is attributable to a $445.6 million increase in internally generated revenue, $53.9 million additional gross profit from acquisitions and an increase of $41.0 million in gross profit due to the increase in the gross margin rates.

Technology and value-added services gross profit increased $41.0 million, or 24.9%, for the six months ended June 26, 2021 compared to the prior year period. The overall increase in our Technology and value-added services gross profit is attributable to an increase of $30.4 million in internally generated revenue and $11.0 million additional gross profit from acquisitions, partially offset by a $0.4 million decline in gross profit. Technology and value-added services gross profit margin increased to 69.7% for the six months ended June 26, 2021 from 69.5% for the comparable prior year period.

Selling, General and Administrative

Selling, general and administrative expenses by segment and in total for the six months ended June 26, 2021 and June 27, 2020 were as follows (in thousands):

 

 

 

 

 

 

% of

 

 

 

 

% of

 

 

 

 

 

 

 

 

 

June 26,

 

Respective

 

June 27,

 

Respective

 

Increase

 

 

 

2021

 

Net Sales

 

2020

 

Net Sales

 

$

 

%

Health care distribution

 

$

1,195,132

 

21.4

%

 

$

912,693

 

23.8

%

 

$

282,439

 

30.9

%

Technology and value-added services

 

 

145,196

 

49.2

 

 

 

121,155

 

51.1

 

 

 

24,041

 

19.8

 

 

Total

 

$

1,340,328

 

22.7

 

 

$

1,033,848

 

25.1

 

 

$

306,480

 

29.6

 

Selling, general and administrative expenses (including restructuring costs in the six months ended June 26, 2021 and June 27, 2020) increased $306.5 million, or 29.6%, for the six months ended June 26, 2021 from the comparable prior year period. In the prior year, there were significant cost-saving measures taken in response to the COVID-19 pandemic. These cost-saving measures were temporary and substantially ended during the second half of 2020.

The $282.4 million increase in selling, general and administrative expenses within our health care distribution segment for the six months ended June 26, 2021 as compared to the prior year period was attributable to an increase of $251.5 million of operating costs and an increase of $47.8 million of additional costs from acquired companies, partially offset by a decrease of $16.9 million in restructuring costs. The $24.0million increase in selling, general and administrative expenses within our technology and value-added services segment for the six months ended June 26, 2021 as compared to the prior year period was attributable to an increase of $15.1 million of operating costs and an increase of $9.2 million of additional costs from acquired companies, partially offset by a decrease of $0.3 million in restructuring costs. As a percentage of net sales, selling, general and administrative expenses decreased to 22.7% from 25.1% for the comparable prior year period, primarily due to the increased sales base.

As a component of total selling, general and administrative expenses, selling expenses increased $164.2 million, or 26.0% to $794.5 million, for the six months ended June 26, 2021 from the comparable prior year period, primarily due to an increase in payroll and payroll related costs. As a percentage of net sales, selling expenses decreased to 13.5% from 15.3% for the comparable prior year period, primarily due to the increased sales base.

As a component of total selling, general and administrative expenses, general and administrative expenses increased $142.3 million, or 35.3% to $545.8 million, for the six months ended June 26, 2021 from the comparable prior year period, primarily due to an increase in payroll and payroll related costs. As a percentage of net sales, general and administrative expenses decreased to 9.2% from 9.8% for the comparable prior year period, primarily due to the increased sales base.

46


Other Expense, Net

Other expense, net, for the six months ended June 26, 2021 and June 27, 2020 was as follows (in thousands):

 

 

 

June 26,

 

June 27,

 

Variance

 

 

 

2021

 

2020

 

$

 

%

Interest income

 

$

3,340

 

$

5,187

 

$

(1,847)

 

(35.6)

%

Interest expense

 

 

(12,861)

 

 

(18,298)

 

 

5,437

 

29.7

 

Other, net

 

 

663

 

 

(511)

 

 

1,174

 

229.7

 

 

Other expense, net

 

$

(8,858)

 

$

(13,622)

 

$

4,764

 

35.0

 

Interest income decreased $1.8 million primarily due to lower interest rates and reduced late fee income. Interest expense decreased $5.4 million primarily due to reduced credit line borrowings and lower interest rates on certain of our private placement borrowings.

Income Taxes

For the six months ended June 26, 2021, our effective tax rate was 24.3% compared to 24.2% for the prior year period. The difference between our effective tax rate and the federal statutory tax rate for the six months ended June 26, 2021, was primarily due to state and foreign income taxes, interest expense and tax charges and credits associated

with legal entity
reorganizations. The difference between our effective tax rates and the federal statutory tax rate for the six months ended June 27, 2020, primarily relates to state and foreign income taxes, interest expense, tax charges and credits associated with legal entity reorganizations outside the United States.U.S and a valuation allowance recognized on a portion of a deferred tax asset.

47


Liquidity and Capital Resources

Our principal capital requirements have included funding of acquisitions, purchases

of additional noncontrolling
interests, repayments of debt principal, the funding of working capital needs,
purchases of fixed assets and
repurchases of common stock (which had been temporarily suspended in March of 2020, but were
resumed during the three months
ended March 27, 2021).
Working capital requirements generally result from increased sales, special inventory
forward buy-in opportunities and payment terms for receivables and
payables.
Historically, sales have tended to be
stronger during the second half of the year and special inventory forward
buy-in opportunities have been most
prevalent just before the end of the year, and have caused our working capital requirements to be higher from
the
end of the third quarter to the end of the first quarter of the following year.

The pandemic and the governmental responses to it had a material adverse

effect on our cash flows in the second
quarter of 2020.
In the latter half of the second quarter of 2020 and continuing
through year-end, dental and
medical practices began to re-open worldwide.
During the first quarterhalf of 2021, patient traffic levels returned to
levels approaching pre-pandemic levels, although certain regions in the U.S.
and internationally are experiencing an
increase in COVID-19 cases.levels. There is an ongoing risk that the COVID-19
pandemic may again have a material
adverse effect on our business, results of operations and cash flows and may result
in a material adverse effect on
our financial condition and liquidity. However, the extent of the potential impact cannot be reasonably estimated at
this time.

We finance our business primarily through cash generated from our operations, revolving credit facilities and debt

placements.
Our ability to generate sufficient cash flows from operations is dependent
on the continued demand of
our customers for our products and services, and access to products and
services from our suppliers.

Our business requires a substantial investment in working capital, which

is susceptible to fluctuations during the
year as a result of inventory purchase patterns and seasonal demands.
Inventory purchase activity is a function of
sales activity, special inventory forward buy-in opportunities and our desired level of inventory.
We anticipate
future increases in our working capital requirements.

We finance our business to provide adequate funding for at least 12 months.

Funding requirements are based on
forecasted profitability and working capital needs, which, on occasion, may
change.
Consequently, we may change
our funding structure to reflect any new requirements.
42

We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets,

and our available funds under existing credit facilities provide us with
sufficient liquidity to meet our currently
foreseeable short-term and long-term capital needs.
We have no off-balance sheet arrangements.

Net cash from continuing operations provided by operating activities was

$63.3 $221.7 million for the threesix months ended
March 27, June 26, 2021, compared to net cash from continuing operations provided
byused in operating activities of $78.8$12.8 million
for the comparable prior year period.
The net change of $15.4$234.6 million was primarily attributable to increased
working capital requirements, specifically an increase in inventories due
to stocking of PPE and other COVID-19
related products, partially offset by decreased accounts receivable due to lower days
sales outstanding. The effect
on operating cash flows from the increased working capital requirements
was partially offset by higher net income.

Net cash from continuing operations used in investing activities was

$223.2 $341.1 million for the threesix months ended
March 27, June 26, 2021, compared to $53.6$69.6 million for the comparable prior
year period.
The net change of $169.6$271.5 million
was attributable to increased payments for equity investments and
business acquisitions.

Net cash from continuing operations used in financing activities was $119.4$139.4 million for the three

six months ended
March 27, June 26, 2021, compared to net cash provided by financing activities
of $491.6$262.1 million for the comparable prior
year period.
The net change of $611.1$401.5 million was primarily due to decreased net proceeds from bank borrowings.borrowings and increased repurchases of common stock.

48


The following table summarizes selected measures of liquidity and capital

resources (in thousands):

 

 

 

 

June 26,

 

December 26,

 

 

 

 

2021

 

2020

Cash and cash equivalents

 

$

167,228

 

$

421,185

Working capital (1)

 

 

1,648,607

 

 

1,508,313

 

 

 

 

 

 

 

 

 

Debt:

 

 

 

 

 

 

 

Bank credit lines

 

$

72,105

 

$

73,366

 

Current maturities of long-term debt

 

 

9,839

 

 

109,836

 

Long-term debt

 

 

706,487

 

 

515,773

 

 

Total debt

 

$

788,431

 

$

698,975

 

 

 

 

 

 

 

 

 

Leases:

 

 

 

 

 

 

 

Current operating lease liabilities

 

$

75,008

 

$

64,716

 

Non-current operating lease liabilities

 

 

243,232

 

 

238,727

 

 

 

 

 

 

 

 

 

(1)

At June 26, 2021 and December 26, 2020, there were no trade accounts receivable that were restricted to settle obligations of this VIE, nor were there liabilities of the VIE where the creditors have recourse to us.

March 27,
December 26,
2021
2020
Cash and cash equivalents
$
144,538
$
421,185
Working
capital
(1)
1,447,857
1,508,313
Debt:
Bank credit lines
$
67,415
$
73,366
Current maturities of long-term debt
111,176
109,836
Long-term debt
506,461
515,773
Total debt
$
685,052
$
698,975
Leases:
Current operating lease liabilities
$
68,580
$
64,716
Non-current operating lease liabilities
248,624
238,727
(1)
At March 27, 2021 and December 26, 2020, there were no trade accounts receivable that were restricted to settle obligations of this VIE,
nor were there liabilities of the VIE where the creditors have recourse to us.

Our cash and cash equivalents consist of bank balances and investments

in money market funds representing
overnight investments with a high degree of liquidity.

Accounts receivable days sales outstanding and inventory turns

Our accounts receivable days sales outstanding from operations decreased

to 42.842.3 days as of March 27,June 26, 2021 from
45.9 52.4 days as of March 28,June 27, 2020.
During the threesix months ended March 27,June 26, 2021, we wrote
off approximately $3.3
$4.6 million of fully reserved accounts receivable against our trade receivable
reserve.
Our inventory turns from
operations increased to 5.25.1 as of March 27,June 26, 2021 from 4.94.2 as of March 28,June 27, 2020.
Our working capital accounts
may be impacted by current and future economic conditions.

43

Bank Credit Lines

Bank credit lines consisted of the following:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Revolving credit agreement

 

$

-

 

$

-

Other short-term bank credit lines

 

 

72,105

 

 

73,366

Total

 

$

72,105

 

$

73,366

March 27,
December 26,
2021
2020
Revolving credit agreement
$
-
$
-
Other short-term bank credit lines
67,415
73,366
Total
$
67,415
$
73,366

Revolving Credit Agreement

On April 18, 2017, we entered into a $750 million revolving credit agreement

(the (the “Credit Agreement”), which
matures in April 2022.
The interest rate is based on the USD LIBOR
plus a spread based on our leverage ratio at
the end of each financial reporting quarter.
We expect most LIBOR rates to be discontinued immediately after
December 31, 2021, while the remaining LIBOR rates will be discontinued
immediately after June 30, 2023, which
will require an amendment to our debt agreements to reflect a new
reference rate. We do not expect the
discontinuation of LIBOR as a reference rate in our debt agreements
to have a material adverse effect on our
financial position or to materially affect our interest expense.
The Credit Agreement also requires, among other
things, that we maintain maximum leverage ratios. Additionally, the Credit Agreement contains customary
representations, warranties and affirmative covenants as well as customary negative
covenants, subject to
negotiated exceptions, on liens, indebtedness, significant corporate changes
(including (including mergers), dispositions and
certain restrictive agreements.
As of March 27,June 26, 2021, and December 26, 2020, we had no borrowings
on under this
revolving credit facility.
As of March 27,June 26, 2021, and December 26, 2020, there were $9.3
million and $9.5 million
of letters of credit, respectively, provided to third parties under the credit facility.

49


On April 17, 2020, we amended the Credit Agreement to, among other

things, (i) modify the financial covenant
from being based on total leverage ratio to net leverage ratio, (ii) adjust the
pricing grid to reflect the net leverage
ratio calculation, and (iii) increase the maximum maintenance leverage ratio
through March 31, 2021.

364-Day Credit Agreement

On March 4, 2021, we repaid the outstanding obligations and terminated

the lender commitments under our $700
million 364-day credit agreement which was entered into on April 17, 2020.
This facility was originally scheduled
to mature on April 16, 2021.

Other Short-Term Credit

Lines

As of March 27,June 26, 2021 and December 26, 2020, we had various other short-term

bank credit lines available, of
which $67.4$72.1 million and $73.4 million, respectively, were outstanding.
At March 27,June 26, 2021 and December 26,
2020, borrowings under all of these credit lines had a weighted average
interest rate of 4.52%5.98% and 4.14%, respectively.

respectively.
44

Long-term debt

Long-term debt consisted of the following:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Private placement facilities

 

$

706,332

 

$

613,498

Note payable

 

 

-

 

 

1,554

Various collateralized and uncollateralized loans payable with interest,

 

 

 

 

 

 

 

in varying installments through 2023 at interest rates

 

 

 

 

 

 

 

ranging from 2.45% to 4.27% at June 26, 2021 and

 

 

 

 

 

 

 

ranging from 2.62% to 4.27% at December 26, 2020

 

 

4,293

 

 

4,596

Finance lease obligations (see Note 6)

 

 

5,701

 

 

5,961

 

Total

 

 

716,326

 

 

625,609

Less current maturities

 

 

(9,839)

 

 

(109,836)

 

Total long-term debt

 

$

706,487

 

$

515,773

50


March 27,
December 26,
2021
2020
Private placement facilities
$
606,355
$
613,498
Note payable
-
1,554
Various
collateralized and uncollateralized loans payable with interest,
in varying installments through 2023 at interest rates
ranging from 2.45% to 4.27% at March 27, 2021 and
ranging from 2.62% to 4.27% at December 26, 2020
5,969
4,596
Finance lease obligations (see Note 7)
5,313
5,961
Total
617,637
625,609
Less current maturities
(111,176)
(109,836)
Total long-term debt
$
506,461
$
515,773

Private Placement Facilities

Our private placement facilities, with three insurance companies,

have a total facility amount of $1 billion, and are
available on an uncommitted basis at fixed rate economic terms to be agreed upon
at the time of issuance, from
time to time through June 23, 2023.
The facilities allow us to issue senior promissory notes to the
lenders at a fixed
rate based on an agreed upon spread over applicable treasury notes at
the time of issuance.
The term of each
possible issuance will be selected by us and can range from five to 15 years
(with (with an average life no longer than 12
years).
The proceeds of any issuances under the facilities will be used
for general corporate purposes, including
working capital and capital expenditures, to refinance existing indebtedness
and/or to fund potential acquisitions.
The agreements provide, among other things, that we maintain
certain maximum leverage ratios, and contain
restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal
of assets and certain changes in
ownership.
These facilities contain make-whole provisions in the event that we
pay off the facilities prior to the
applicable due dates.

On March 5, 2021, we amended the private placement facilities

to, among other things, (a) modify the financial
covenant from being based on a net leverage ratio to a total leverage
ratio and (b) restore the maximum
maintenance total leverage ratio to 3.25x and remove the 1.00% interest
rate increase triggered if the net leverage
ratio were to exceed 3.0x.

The components of our private placement facility borrowings as

of March 27,June 26, 2021 are presented in the following
table (in thousands):

 

 

 

 

 

 

 

 

 

 

 

Amount of

 

 

 

 

 

 

 

Borrowing

 

Borrowing

 

 

Date of Borrowing

 

Outstanding

 

Rate

 

Due Date

January 20, 2012 (1)

 

$

7,143

 

3.09

%

 

January 20, 2022

January 20, 2012

 

 

50,000

 

3.45

 

 

January 20, 2024

December 24, 2012

 

 

50,000

 

3.00

 

 

December 24, 2024

June 16, 2017

 

 

100,000

 

3.42

 

 

June 16, 2027

September 15, 2017

 

 

100,000

 

3.52

 

 

September 15, 2029

January 2, 2018

 

 

100,000

 

3.32

 

 

January 2, 2028

September 2, 2020

 

 

100,000

 

2.35

 

 

September 2, 2030

June 2, 2021

 

 

100,000

 

2.48

 

 

June 2, 2031

June 2, 2021

 

 

100,000

 

2.58

 

 

June 2, 2033

Less: Deferred debt issuance costs

 

 

(811)

 

 

 

 

 

 

 

$

706,332

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.

Amount of
Borrowing
Borrowing
Date of Borrowing
Outstanding
Rate
Due Date
January 20, 2012
(1)
$
7,143
3.09
%
January 20, 2022
January 20, 2012
50,000
3.45
January 20, 2024
December 24, 2012
50,000
3.00
December 24, 2024
June 2, 2014
100,000
3.19
June 2, 2021
June 16, 2017
100,000
3.42
June 16, 2027
September 15, 2017
100,000
3.52
September 15, 2029
January 2, 2018
100,000
3.32
January 2, 2028
September 2, 2020
100,000
2.35
September 2, 2030
Less: Deferred debt issuance costs
(788)
$
606,355
(1)
Annual repayments of approximately $7.1 million for this borrowing commenced on January 20, 2016.
45

U.S. Trade Accounts Receivable Securitization

We have a facility agreement with a bank, as agent, based on the securitization of our U.S. trade accounts

receivable that is structured as an asset-backed securitization program with pricing
committed for up to three years.
Our current facility, which has a purchase limit of $350 million, was scheduled to expire on April 29, 2022.
On
June 22, 2020, the expiration date for this facility was extended to
June 12, 2023 and was amended to adjust certain
covenant levels for 2020.
As of March 27,June 26, 2021 and December 26, 2020, there were no borrowings
outstanding
under this securitization facility.
At March 27,June 26, 2021, the interest rate on borrowings under this
facility was based
on the asset-backed commercial paper rate of 0.18%0.14% plus 0.95%, for a combined
rate of 1.13%1.09%.
At December 26,
2020, the interest rate on borrowings under this facility was based
on the asset-backed commercial paper rate of
0.22% plus 0.95%, for a combined rate of 1.17%.

If our accounts receivable collection pattern changes due to customers either

paying late or not making payments,
our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 25 to 45 basis points depending upon program utilization.

51


Leases

We have operating and finance leases for corporate offices, office space, distribution and other facilities, vehicles,

and certain equipment.
Our leases have remaining terms of less than one year to
approximately 15 years, some of
which may include options to extend the leases for up to 10 years.
As of March 27,June 26, 2021, our right-of-use assets
related to operating leases were $301.8$301.4 million and our current and non-current
operating lease liabilities were
$68.6 $75 million and $248.6$243.2 million, respectively.

Stock Repurchases

On March 8, 2021, we announced the reinstatement of our share repurchase

program.

From March 3, 2003 through March 27,June 26, 2021, we repurchased $3.7$3.8 billion,

or 76,888,53178,430,846 shares, under our
common stock repurchase programs, with $112.6$400.0 million available as of March 27,June 26, 2021 for future
common stock
share repurchases.

Redeemable Noncontrolling Interests

Some minority stockholders in certain of our subsidiaries have the right,

at certain times, to require us to acquire
their ownership interest in those entities at fair value.
Accounting Standards Codification Topic 480-10 is
applicable for noncontrolling interests where we are or may be required
to purchase all or a portion of the
outstanding interest in a consolidated subsidiary from the noncontrolling
interest holder under the terms of a put
option contained in contractual agreements.
The components of the change in the redeemable noncontrolling
interests for the threesix months ended March 27,June 26, 2021 and the year ended December
26, 2020 are presented in the
following table:

 

 

 

June 26,

 

December 26,

 

 

 

2021

 

2020

Balance, beginning of period

 

$

327,699

 

$

287,258

Decrease in redeemable noncontrolling interests due to

 

 

 

 

 

 

 

redemptions

 

 

(1,130)

 

 

(17,241)

Increase in redeemable noncontrolling interests due to business

 

 

 

 

 

 

 

acquisitions

 

 

140,155

 

 

28,387

Net income attributable to redeemable noncontrolling interests

 

 

14,033

 

 

13,363

Dividends declared

 

 

(9,954)

 

 

(12,631)

Effect of foreign currency translation gain (loss) attributable to

 

 

 

 

 

 

 

redeemable noncontrolling interests

 

 

570

 

 

(4,279)

Change in fair value of redeemable securities

 

 

132,708

 

 

32,842

Balance, end of period

 

$

604,081

 

$

327,699

March 27,
December 26,
2021
2020
Balance, beginning of period
$
327,699
$
287,258
Decrease in redeemable noncontrolling interests due to
redemptions
-
(17,241)
Increase in redeemable noncontrolling interests due to business
acquisitions
85,037
28,387
Net income attributable to redeemable noncontrolling interests
7,053
13,363
Dividends declared
(6,237)
(12,631)
Effect of foreign currency translation loss attributable to
redeemable noncontrolling interests
(6,173)
(4,279)
Change in fair value of redeemable securities
45,520
32,842
Balance, end of period
$
452,899
$
327,699
46

Changes in the estimated redemption amounts of the noncontrolling

interests subject to put options are adjusted at
each reporting period with a corresponding adjustment to Additional paid-in
capital.
Future reductions in the
carrying amounts are subject to a floor amount that is equal to the
fair value of the redeemable noncontrolling
interests at the time they were originally recorded.
The recorded value of the redeemable noncontrolling interests
cannot go below the floor level.
These adjustments do not impact the calculation of earnings per
share.

Additionally, some prior owners of such acquired subsidiaries are eligible to receive additional purchase price cash

consideration if certain financial targets are met.
Any adjustments to these accrual amounts are recorded in our
consolidated statements
of income.
For the threesix months ended March 27,June 26, 2021 and March 28,June 27, 2020,
there were no
material adjustments recorded in our consolidated statements
of income relating to changes in estimated contingent
purchase price liabilities.

Noncontrolling Interests

Noncontrolling interests represent our less than 50% ownership interest

in an acquired subsidiary. Our net income
is reduced by the portion of the subsidiaries net income that is attributable
to noncontrolling interests.

52


Critical Accounting Policies and Estimates

There have been no material changes in our critical accounting policies and

estimates from those disclosed in Item
7 of our Annual Report on Form 10-K for the year ended December 26, 2020,
except accounting policies adopted
as of December 27, 2020, which are discussed in
of the Notes to the Consolidated Financial Statements included
under Item 1.

Our financial results for the threesix months ended MarchJune 27, 20212020 were

affected by certain estimates we made due to
the adverse business environment brought on by the COVID-19 pandemic.
For example, in the quarter ended
March 28, 2020 we recorded incremental bad debt reserves of approximately
$10.0 $10.0 million for our global dental
business.
During the quarter ended March 28, 2020, we also recognized a net credit
of approximately $17.5 million
in stock-based compensation
expense due to our estimate that no performance shares granted in 2018,
2019 or 2020
would ultimately vest.
For the quarter ended June 27, 2020, we continued to estimate that no such performance-based shares would ultimately vest. In contrast, for the threesix months ended March 27,June 26, 2021, we
recorded $12.8$30.2 million in stock-
based compensation expense.
stock-based compensation. Additionally, in the quarter ended March 28, 2020, we recorded total impairment
charges of approximately $6.1 million related to prepaid royalty expenses and a customer
relationship intangible
asset.
We had no material impairment charges in the quarter ended March 27,June 26, 2021.
Although our selling, general
and administrative expenses for the threesix months ended March 27,June 26, 2021
represent management's best estimates and
assumptions that affect the reported amounts, our judgment could change in the future due
to the significant
uncertainty surrounding the macroeconomic effect of the COVID-19 pandemic.

Accounting Standards Update

For a discussion of accounting standards updates that have been adopted

or will be adopted, see
of the Notes
to the Consolidated Financial Statements included under Item 1.

ITEM 3.

QUANTITATIVE
AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK

There have been no material changes in our exposure to market risk

from that disclosed in Item 7A of our Annual
Report on Form 10-K for the year ended December 26, 2020.

53


47

ITEM 4.

CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of management, including

our principal executive officer and
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and
procedures as of the end of the period covered by this quarterly report
as such term is defined in Rules 13a-15(e)
and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”). Based
on this evaluation, our management, including our principal executive officer and principal
financial officer,
concluded that our disclosure controls and procedures were effective as of March
27,June 26, 2021, to ensure that all
material information required to be disclosed by us in reports that we file
or submit under the Exchange Act is
accumulated and communicated to them as appropriate to allow timely
decisions regarding required disclosure and
that all such information is recorded, processed, summarized and reported
within the time periods specified in the
SEC’s rules and forms.

Changes in Internal Control over Financial Reporting

The combination of acquisitions, and continued acquisition integrations and system implementation undertaken

during the quarter and carried
over from prior quarters, as well as changes to the operating methods of some
of our internal controls over financial
reporting due to the COVID-19 pandemic, when considered in the aggregate,
represents a material change in our
internal control over financial reporting.

During the quarter ended March 27,June 26, 2021, we completed the acquisitionacquisitions of

a technology and value added-services business and a dental and medical businesses in North
America and Europebusiness with approximatecombined aggregate annual revenues of approximately
$354 $60 million.
In addition,
post-acquisition integration related activities continued for our North American
medical and global dental
businesses acquired during prior quarters, representing aggregate annual
revenues of approximately $299
$600 million.
These acquisitions, the majority of which utilize separate
information and financial accounting systems,
have been included in our consolidated financial statements since their respective
dates of acquisition.

Also, during the quarter ended June 26, 2021, we completed systems implementation activities to upgrade the equipment system for our U.S. dental and medical businesses representing aggregate projected annual revenues of approximately $960 million.

All acquisitions, and continued acquisition integrations and system implementation involve necessary

and appropriate change-management
controls that are considered in our quarterly assessment of the design and
operating effectiveness of our internal
control over financial reporting.

In addition, as a result of a combination of continued governmental imposed

and Company directed closures of
some of our facilities due to the COVID-19 pandemic, we have had
to maintain a number of changes to the
operating methods of some of our internal controls. For example, moving
from manual sign-offs and in-person
meetings to electronic sign-offs and electronic communications such as email and
telephonic or video conference
due to out-of-office working arrangements. However, the design of our internal control framework and objectives
over financial reporting remains unchanged and we do not believe that these
changes have materially affected, or
are reasonably likely to materially affect, the effectiveness of our internal control over financial
reporting.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide

only reasonable, not absolute, assurance
that the objectives of the internal control system are met. Because of
the inherent limitations of any internal control
system, no evaluation of controls can provide absolute assurance that
all control issues, if any, within a company
have been detected.

54


48

PART

II.
OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

For a discussion of Legal Proceedings, see

of the Notes to the Consolidated Financial
Statements included under Item 1.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors disclosed in

Part 1, Item 1A, of our Annual Report on
Form 10-K for the year ended December 26, 2020.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS

Purchases of equity securities by the issuer

Our share repurchase program announced on March 3, 2003

, originally allowed us to repurchase up to two million
shares pre-stock splits (eight million shares post-stock splits) of our common
stock, which represented
approximately 2.3%
of the shares outstanding at the commencement of the program.
Subsequent additional
increases totaling $3.7 billion, authorized by our Board of Directors,
to the repurchase program provide for a total
of $3.8 billion of shares of our common stock to be repurchased under this program.

program.

On March 8, 2021, we announced the reinstatement of our share repurchase

program.

As of March 27,June 26, 2021, we had repurchased approximately $3.7$3.8 billion of common

stock (76,888,531(78,430,846 shares) under
these initiatives, with $112.6$400.0 million available for future common stock share repurchases.

The following table summarizes repurchases of our common stock

under our stock repurchase program during the
fiscal quarter ended March 27,June 26, 2021.

 

 

 

 

 

 

 

 

Total Number

 

Maximum Number

 

 

 

Total

 

 

 

 

of Shares

 

of Shares

 

 

 

Number

 

Average

 

Purchased as Part

 

that May Yet

 

 

 

of Shares

 

Price Paid

 

of Our Publicly

 

Be Purchased Under

Fiscal Month

 

Purchased (1)

 

Per Share

 

Announced Program

 

Our Program (2)

3/28/21 through 4/24/2021

 

744,696

 

$

69.25

 

744,696

 

6,210,991

4/25/21 through 5/29/2021

 

528,823

 

 

75.98

 

528,823

 

5,533,921

5/30/21 through 6/26/2021

 

268,796

 

 

77.38

 

268,796

 

5,332,623

 

 

1,542,315

 

 

 

 

1,542,315

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) All repurchases were executed in the open market under our existing publicly announced authorized program.

 

 

 

 

 

 

 

 

 

 

 

(2) The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the closing price of our common stock at that time. This table excludes shares withheld from employees to satisfy minimum tax withholding requirements for equity-based transactions.

Total Number

55


Maximum Number
Total
of Shares
of Shares
Number
Average
Purchased as Part
that May Yet
of Shares
Price Paid
of Our Publicly
Be Purchased Under
Fiscal Month
Purchased (1)
Per Share
Announced Program
Our Program (2)
12/27/20 through 1/30/2021
-
$
-
-
3,055,600
1/31/21 through 2/27/2021
-
-
-
3,253,214
2/28/21 through 3/27/2021
1,325,242
66.90
1,325,242
1,655,664
1,325,242
1,325,242
(1)
All repurchases were executed in the open market under our existing publicly announced authorized program.
(2)
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the
closing price of our common stock at that time.
This table excludes shares withheld from employees to satisfy minimum tax withholding
requirements for equity-based transactions.
49

ITEM 6.

EXHIBITS
.
2021.)
.
2021.)
.
2021.)
.
2021.)**
101.INS
Inline XBRL Instance Document - the instance document does not appear
in the
Interactive Data File because its XBRL tags are embedded within the Inline
XBRL document+
101.SCH
Inline XBRL Taxonomy Extension Schema Document+
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document+
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document+
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document+
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document+
104
The cover page of Henry Schein, Inc.’s Quarterly Report on Form 10-Q for the
quarter ended March 27, 2021, formatted in Inline XBRL (included within
Exhibit 101 attachments).+
+ Filed or furnished herewith.

** Indicates management contract or compensatory plan or agreement.

56


50

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the

Registrant has duly caused this Report to
be signed on its behalf by the undersigned thereunto duly authorized.

Henry Schein, Inc.

(Registrant)

By: /s/ Steven Paladino

Steven Paladino

Executive Vice President and

Chief Financial Officer

(Authorized Signatory and Principal Financial

and Accounting Officer)

Dated: August 3, 2021

Henry Schein, Inc.
(Registrant)
By: /s/ Steven Paladino
Steven Paladino
Executive Vice President and
Chief Financial Officer
(Authorized Signatory and Principal Financial
and Accounting Officer)
Dated: May 4, 2021

57